

Research Articles: Neurobiology of Disease

MicroRNA-1224 splicing circularRNA-Filip1I in an Ago2- dependent manner regulates chronic inflammatory pain via targeting Ubr5

Zhiqiang Pan^{1,2}, Guo-Fang Li^{1,2}, Meng-Lan Sun^{1,2}, Ling Xie^{1,2}, Di Liu^{1,2}, Qi Zhang^{1,2}, Xiao-Xiao Yang^{1,2}, Sunhui Xia^{1,2}, Liu Xiaodan^{1,2}, Huimin Zhou^{1,2}, Zhou-Ya Xue^{1,2}, Ming Zhang^{1,2}, Ling-Yun Hao^{1,2}, Li-Jiao Zhu^{1,2} and Jun-Li Cao^{1,2,3}

¹Jiangsu Province Key Laboratory of Anesthesiology, Xuzhou Medical University, Xuzhou 221004, China.

²Jiangsu Province Key Laboratory of Anesthesia and Analgesia Application Technology, Xuzhou Medical University, Xuzhou 221004, China.

³Department of Anesthesiology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, China.

<https://doi.org/10.1523/JNEUROSCI.1631-18.2018>

Received: 29 June 2018

Revised: 10 December 2018

Accepted: 26 December 2018

Published: 16 January 2019

Author contributions: J.-L.C. and Z.P. designed research; J.-L.C. and Z.P. wrote the paper; Z.P., G.-F.L., M.S., L.X., D.L., Q.Z., X.-X.Y., S.X., X.L., H.Z., Z.-Y.X., M.Z., and L.H. performed research; Z.P. contributed unpublished reagents/analytic tools; Z.P., G.-F.L., M.S., L.H., and L.Z. analyzed data; Z.P. wrote the first draft of the paper.

Conflict of Interest: The authors declare no competing financial interests.

The study was supported by grants from the National Natural Science Foundation of China (81671096, 81271231 to Z. Pan, 31771161, 81720108013 to J.-L. Cao, 31500855 to L.-J. Zhu); Key project of the Natural Science Foundation of Jiangsu Education Department (15KJA320004 to Z. Pan); and the Project Funded by the Qing Lan Project, by the Six Talent Summit Project, by the 333 High-level Personnel Training Project.

Correspondence: Address correspondence: Jiangsu Province Key Laboratory of Anesthesiology, Xuzhou Medical University, 209 Tongshan Road, Xuzhou 221004, Jiangsu, PR China. Tel.: +86-516-83262686; E-mail to Dr. Zhiqiang Pan: zhiqiangp2002@aliyun.com; or to Dr. Jun-Li Cao: caojl0310@aliyun.com

Cite as: J. Neurosci 2019; 10.1523/JNEUROSCI.1631-18.2018

Alerts: Sign up at www.jneurosci.org/alerts to receive customized email alerts when the fully formatted version of this article is published.

Accepted manuscripts are peer-reviewed but have not been through the copyediting, formatting, or proofreading process.

Copyright © 2019 the authors

1 **Title page**

2

3 **MicroRNA-1224 splicing circularRNA-Filip1I in an Ago2-**
4 **dependent manner regulates chronic inflammatory pain via**
5 **targeting Ubr5**

6

7 Zhiqiang Pan,^{1,2} * Guo-Fang Li,^{1,2} * Meng-Lan Sun,^{1,2} * Ling Xie,^{1,2} Di Liu,^{1,2}
8 Qi Zhang,^{1,2} Xiao-Xiao Yang,^{1,2} Sunhui, Xia,^{1,2} Xiaodan Liu,^{1,2} Huimin Zhou,^{1,2}
9 Zhou-Ya Xue,^{1,2} Ming Zhang,^{1,2} Ling-Yun Hao,^{1,2} Li-Jiao Zhu,^{1,2} and Jun-Li
10 Cao^{1,2,3}

11

12 ¹ Jiangsu Province Key Laboratory of Anesthesiology, Xuzhou Medical University,
13 Xuzhou 221004, China.

14 ²Jiangsu Province Key Laboratory of Anesthesia and Analgesia Application
15 Technology, Xuzhou Medical University, Xuzhou 221004, China.

16 ³Department of Anesthesiology, The Affiliated Hospital of Xuzhou Medical
17 University, Xuzhou 221002, China.

18

19 **Correspondence**

20 Address correspondence: Jiangsu Province Key Laboratory of Anesthesiology,
21 Xuzhou Medical University, 209 Tongshan Road, Xuzhou 221004, Jiangsu, PR

22 China. Tel.: +86-516-83262686; E-mail to Dr. Zhiqiang Pan: zhiqiangp2002@
23 aliyun.com; or to Dr. Jun-Li Cao: caojl0310@aliyun.com

24

25 **Acknowledgements**

26 The study was supported by grants from the National Natural Science Foundation
27 of China (81671096, 81271231 to Z. Pan, 31771161, 81720108013 to J.-L. Cao,
28 31500855 to L.-J. Zhu); Key project of the Natural Science Foundation of Jiangsu
29 Education Department (15KJA320004 to Z. Pan); and the Project Funded by the
30 Qing Lan Project, by the Six Talent Summit Project, by the 333 High-level
31 Personnel Training Project.

32

33 **Author contributions**

34 Z.P, G.F.L, and M.L.S contributed equally to this work.
35 J.-L.C. and Z.P. designed research; Z.P., G.-F.L., M.-L.S., L.X., D.L., Q.Z., X.-X.Y.,
36 Z.-Y.X., M.Z., L.-Y.H., S.X., X. L., and H. Z. performed research; Z.P., G.-F.L.,
37 M.-L.S., H.-L.D., and L.-J.Z. analyzed data; J.-L.C. and Z.P. wrote the paper.

38

39 **Words statistics**

40 Number of words in Abstract: 225

41 Number of words in Introduction: 754

42 Number of words in Discussion: 1798

43 **Figure statistics**

44 Number of figures: 8

45

46

47 **Running head**

48 CircRNA-Filip1l regulates chronic pain

49

50 **Competing Interests**

51 The authors declare no competing interests.

52

53

54

55

56

57

58

59

60

61

62

63

64 **Abstract**

65

66 Dysfunctions of genes transcription and translation in the nociceptive pathways
67 play the critical role in development and maintenance of chronic pain. Circular
68 RNAs (circRNAs) are emerging as new players in regulation of gene expression,
69 but whether and how circRNAs are involved in chronic pain remains elusive. We
70 showed here that complete Freund's adjuvant (CFA)-induced chronic
71 inflammation pain significantly increased circRNA-Filip1l (filamin A interacting
72 protein 1-like) expression in spinal neurons of mice. Blockage of this increase
73 attenuated CFA-induced nociceptive behaviors, and overexpression of spinal
74 circRNA-Filip1l in naïve mice mimicked the nociceptive behaviors as evidenced
75 by decreased thermal and mechanical nociceptive threshold. Furthermore, we
76 found that mature circRNA-Filip1l expression was negatively regulated by
77 miRNA-1224 via binding and splicing of precursor of circRNA-Filip1l
78 (pre-circRNA-Filip1l) in the Argonaute-2 (Ago2)-dependent manner. Increase of
79 spinal circRNA-Filip1l expression resulted from the decrease of miRNA-1224
80 expression under chronic inflammation pain state. MiRNA-1224 knockdown or
81 Ago2 overexpression induced nociceptive behaviors in naïve mice, which was
82 prevented by the knockdown of spinal circRNA-Filip1l. Finally, we demonstrated
83 that an ubiquitin protein ligase E3 component n-recognin 5 (Ubr5), validated as a
84 target of circRNA-Filip1l, plays a pivotal role in regulation of nociception by spinal

85 circRNA-Filip1l. These data suggest that miRNA-1224-mediated and
86 Ago2-dependent modulation of spinal circRNA-Filip1l expression regulates
87 nociception via targeting Ubr5, revealing a novel epigenetic mechanism of
88 interaction between miRNA and circRNA in chronic inflammation pain.

89

90 **Key words:** circRNA; miRNA; Ubr5; nociception; spinal cord

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106 **Significance Statement**

107

108 CircRNAs are emerging as new players in regulation of gene expression. Here,
109 we found that the increase of circRNA-Filip1l mediated by miRNA-1224 in
110 Ago2-dependent way in the spinal cord is involved in regulation of nociception via
111 targeting Ubr5. Our study reveals a novel epigenetic mechanism of interaction
112 between miRNA and circRNA in chronic inflammation pain.

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127 **Introduction**

128

129 Emerging evidence has shown that malfunctions in regulation of gene expression
130 mediated by epigenetic mechanisms play the critical role in development and
131 maintenance of chronic pain induced by diverse causes (Imai et al., 2013; Ji et al.,
132 2016; Pan et al., 2016; Jiang et al., 2017). The existing body of research suggests
133 that the epigenetic regulation of gene expression by the widespread noncoding
134 RNAs (ncRNAs) including miRNA and long ncRNA is involved in the process of
135 inflammation or nerve injury-induced chronic pain (Zhao et al., 2013; Park et al.,
136 2014; Jiang et al., 2016). However, the study of pain-related circular RNAs
137 (circRNAs, a kind of ncRNAs) is still in its infancy.

138 CircRNAs, a large class of circularized RNAs in different species ranging from
139 human and mouse to *Drosophila* and *C. elegans*, are characterized by a high
140 stable structure and high tissue-specific expression (You et al., 2015; Chen and
141 Schuman, 2016). Their expression is associated with such physiological and
142 pathological processes as metabolism, cancer (Hansen et al., 2013a),
143 atherosclerosis (Holdt et al., 2016), and myogenesis (Legnini et al., 2017).
144 However, how they are causally linked to disease development remains elusive.
145 Recent studies reveal that several circRNAs are specifically enriched in brain
146 (Memczak et al., 2013; You et al., 2015; Chen and Schuman, 2016) or spinal cord
147 (Zhou et al., 2017). Interestingly, these circRNAs are differentially expressed in

148 various brain regions or in neuronal subcellular fraction, and notably involved in
149 brain development, neuronal differentiation and synaptic plasticity (Rybak-Wolf et
150 al., 2015). These characteristics imply their potential involvement in the
151 pathogenesis of a variety of central nervous system (CNS) diseases.
152 Accumulating evidence indicates that their aberrant expression or functional
153 consequences contribute to the initiation, development, maintenance of various
154 neurological disorders such as epilepsy, Parkinson's disease (PD) (Kumar et al.,
155 2018), Alzheimer's disease (AD) (Shao and Chen, 2016), and pain (Cao et al.,
156 2017; Zhou et al., 2017). The expression profiling shows that spared nerve injury
157 (SNI) leads to 68 up-regulation and 120 down-regulation of circRNAs in rat spinal
158 cord, furthermore, *in vitro* luciferase assay shows that circ-0006928 regulates
159 chronic pain by targeting miRNA-184 (Zhou et al., 2017). Despite the fact in favor
160 of circRNA's relevant potential therapeutic tool for CNS-related diseases, the role
161 of circRNAs in the aberrant gene expression has not been explored in chronic
162 pain. CircRNA-Filip1I, named as circ-0000691 in circbase data (Memczak et al.,
163 2013), is firstly found in mouse cerebella tissue (Glazar et al., 2014), and its
164 expression is further confirmed in mammalian brain (Rybak-Wolf et al., 2015). Our
165 circRNA profiling showed that circRNA-Filip1I was significantly increased in the
166 spinal cord of complete Freund's adjuvant (CFA)-induced chronic inflammatory
167 pain mice. However, it is unclear whether and how circRNA-Filip1I participates in
168 the process of chronic pain.

169 Recently, a strong link between miRNA dysregulation and chronic pain has
170 been established (Descalzi et al., 2015). Manipulation of miRNA expression in
171 pain pathways from primary afferent nociceptors, DRG, spinal cord, and brain
172 associated with pain perception prevents or reverses persistent inflammatory,
173 neuropathic, and cancer pain behavior by post-transcription in cytoplasm (Park
174 et al., 2014; Jiang et al., 2016; Gandla et al., 2017; Zhang et al., 2017). Growing
175 findings suggest that the majority of miRNAs exist in both nucleus and cytoplasm,
176 and some are preferentially enriched in the nucleus (Roberts, 2014; Rasko and
177 Wong, 2017). Furthermore, the assembled Ago2-miRNA complexes are required
178 for modulation of splicing or transcription of mRNA or circRNA through miRNA
179 binding in nucleus. MiRNA-671 directs the cleavage of a circular antisense
180 transcript of cerebellar degeneration-related protein 1 (CDR1) in Ago2-dependent
181 manner in nucleus, resulting in the down-regulation of circular antisense,
182 suggesting a crucial function of miRNA-mediated Ago2 cleavage in the
183 modulation of circRNA expression (Hansen et al., 2011). MiRNA-1224 is relatively
184 conserved in mammal cells, and is abundantly expressed in CNS tissues such as
185 brain cerebral (Hunsberger et al., 2012), hippocampus and the marginal division
186 (Shu et al., 2013). In HEK293T cell, up-regulation of miRNA-1224 with mimics
187 silences the expression of LRRK2 and α -synuclein associated with PD (Sibley et
188 al., 2012), supporting the potential regulatory role of miRNA-1224 in CNS

189 diseases-related genes. However, it is still unknown whether miRNA-1224 is
190 involved in chronic pain.

191 In the current work, we found the increase of circRNA-Filip1l and decrease of
192 miRNA-1224 in mouse spinal cords in a CFA-induced inflammation pain model.
193 Moreover, miRNA-1224 is predictively bound to the splice junction of
194 precursor-circRNA-Filip1l (pre-circRNA-Filip1l). Thus, we hypothesized that the
195 circRNA-Filip1l cleaved by miRNA-1224 in an Ago2-dependent manner
196 contributes to the development and maintenance of chronic inflammatory pain.

197

198

199

200

201

202

203

204

205

206

207

208

209

210 **Materials and Methods**

211

212 *Animals, pain model, and behavior testing.* All animal procedures were approved
213 by the animal care committee of Xuzhou Medical University (Xuzhou, China). All
214 efforts were made to minimize animal suffering and to reduce the number of
215 animals used. Mice were housed at 23 ± 3 °C with humidity ranges between 25
216 and 45%, and maintained on a 12:12 light / dark cycle (06:00 to 18:00 h) with
217 access to food and water *ad libitum*. Adult male Shanghai populations of Kunming
218 mice (20 - 25 g) were used in this study. The animals were randomized to either a
219 control or an experimental group. Chronic inflammatory pain was induced by
220 subcutaneous administration of CFA (40 μ l; F5881; Sigma-Aldrich, USA) into the
221 plantar surface of the left hind paw. A 0.9% saline solution was used as a control
222 for CFA. Unilateral sciatic nerve chronic constrictive injury (CCI) model was
223 performed as described (Pan et al., 2014). Mice were anesthetized with inhalation
224 anesthesia by isoflurane in O₂. Under the anesthesia condition: blunt dissection
225 was made into the skin overlying the area between the gluteus and biceps femoris
226 muscles, and the common left sciatic nerve of the hind paw was exposed at the
227 mid-thigh level. Approximately 7mm of nerve was freed, proximal to the sciatic
228 trifurcation, and three loose ligatures (about 1 mm space) of 7-0 silk thread were
229 placed around the sciatic nerve, until a brief twitch was observed. Sham-operative
230 groups underwent identical procedures but no ligation of the respective nerve.

231 After surgery, all mice were maintained in a warm electric blanket with stable
232 temperature until they recovered from anesthesia.

233 Paw withdrawal latency to a thermal stimulus and paw withdrawal thresholds
234 to a mechanical stimulus were used to measure hyperalgesia and allodynia as
235 described previously (Pan et al., 2017). Before nociceptive behavior testing, mice
236 were acclimatized to the environment for 1h. Thermal hyperalgesia was assessed
237 with an analgesia meter (IITC Model 336 Analgesia Meter, Series 8; IITC Life
238 Science Inc.; Woodland Hills, CA, USA) by focusing a beam of light on the plantar
239 surface of the hind paw to generate heat. The time required for the stimulus to
240 elicit withdraw of the hind paw was recorded. The radiant heat intensity was
241 adjusted to obtain basal paw withdrawal latency of 11 to 14s. An automatic 20s
242 cutoff was used to prevent tissue damage. Thermal stimuli were delivered three
243 times to each hind paw at 5-min intervals. Mechanical allodynia was assessed
244 with the use of Von Frey filaments (Stoelting Inc., Chicago, IL, USA), starting with
245 a 0.16g and ending with a 6.0g filament. The filaments were presented five times
246 respectively at 5 min intervals, in ascending order of strength, perpendicular to the
247 plantar surface with sufficient force to cause slight bending against the paw. A
248 brisk withdrawal or flinching of the paw was considered a positive response. All
249 behavioral tests were performed in a double blind trial fashion in this study.

250

251 *Locomoters function.* Three reflex tests were carried out as follows. To test the
252 grasping reflex, climbing tests were carried out according to previously described
253 procedures (Zhang et al., 2014). A 0.5mm diameter metal wire mesh with a 5mm
254 wide grid was placed vertically 30cm above the table. Each mouse started at the
255 bottom of the mesh with its head facing downward. After the mouse was released,
256 the time required for it to climb all the way to the top was recorded. A maximum
257 time of 60s was applied for animals that could not successfully complete this task.
258 Two sessions were performed for each mouse with a 30min interval, and the
259 shorter time was recorded. To test the placing reflex (Tao et al., 2003), we held
260 the mouse with the hind limbs slightly lower than the forelimbs and brought the
261 dorsal surfaces of the hind paws into contact with the edge of a table. The
262 experimenter recorded whether the hind paws were placed on the table surface
263 reflexively. To test the righting reflex (Tao et al., 2003), we placed the mouse on
264 its back on a flat surface; the experimenter noted whether it immediately assumed
265 the normal upright position. Scores for placing, grasping, and righting reflexes
266 were based on the counts of each normal reflex exhibited in five trials.

267

268 *Spinal tissue collection.* Mice were anesthetized with 10% chloral hydrate, and the
269 spinal cord within the lumbar segments (L3-L5) was removed rapidly. The dorsal
270 spinal cord ipsilateral to CFA was separated and snap-frozen in liquid nitrogen,
271 and stored at -80°C .

272 *CircRNA-microarray*. Total RNA from each of 6 samples was quantified using the
273 NanoDrop ND-2000. The sample preparation and microarray hybridization were
274 performed according to Arraystar Mouse circRNA's standard protocols (Arraystar
275 Inc.). Briefly, total RNA from each sample was firstly treated with Rnase R
276 (Epicentre, Inc.) to obtain circRNA through removing linear RNAs. Then, each
277 sample was amplified and transcribed into fluorescent cRNA utilizing a random
278 priming method (Arraystar Super RNA Labeling Kit; Arraystar). The labeled
279 cRNAs were purified by RNeasy Mini Kit (Qiagen). The concentration and specific
280 activity of the labeled cRNAs (pmol Cy3/ μ g cRNA) were measured by NanoDrop
281 ND-2000. 1 μ g of each labeled cRNA was fragmented by adding 5 μ l 10 \times Blocking
282 Agent and 1 μ l of 25 \times Fragmentation buffer, then heated the mixture at 60 $^{\circ}$ C for
283 30min, finally 25 μ l 2 \times Hybridization buffer was added to dilute the labeled cRNA.
284 50 μ l of hybridization solution was dispensed into the gasket slide and assembled
285 to the circRNA expression microarray slide (6 x 7K, Arraystar). The slides were
286 incubated for 17h at 65 $^{\circ}$ C in an Agilent Hybridization Oven. After having washed
287 the slides, the arrays were scanned by the Axon GenePix 4000B microarray
288 scanner. Scanned images were then imported into GenePix Pro 6.0 software
289 (Axon) for grid alignment and data extraction. Quantile normalization and
290 subsequent data processing was performed using the R software package. After
291 quantile normalization of the raw data, low intensity filtering was performed, and
292 the circRNAs that at least 1 out of 3 samples have flag "expressed" (greater than

293 2 times background standard deviation) were retained for further analyses.
294 Differentially expressed circRNAs with statistical significance between two groups
295 were identified through Volcano Plot filtering. The statistical significance of the
296 difference was conveniently estimated by t-test. CircRNAs having fold changes ≥ 2
297 and p-values ≤ 0.05 were selected as the significantly differentially expressed.

298

299 *RNA, circRNA, miRNA, and RT-qPCR.* Total RNA was isolated with a Trizol
300 reagent (15596-026; Invitrogen, USA) to generate cDNA templates by reverse
301 transcription reactions with oligo (dT) for Ago2, and Filip1l, or with random primers
302 for circRNA-Filip1l, and pre-circRNA-Filip1l, and reverse transcriptase M-MLV
303 (2641A; Takara Bio, Japan) at 42°C for 60 min. cDNA products were used as
304 templates to detect gene mRNA (Ago2: F: 5'-CGTCCTTCCCCTACCACG-3', R:
305 5'-CCAGAGGTATGGCTTCCTTCA-3'; Ubr5: F: 5'-TGAGGTTTCTACGATCTGTG
306 GC-3', R: 5'-AAACACACGTTTGCATTTTCCA-3'; Filip1l: F: 5'-CACA GGGTAAA
307 CTAGCCCTTG-3'; R: 5'-TGGCGATTTTGACTGTCCTCA-3' and pre-circRNA-
308 Filip1l: F: 5'-CTCTGGTCACCTGGTGGGAT-3', R: 5'-TGGGTAGAGGCAATTTG
309 GCA-3') or circRNA expression (circRNA-Filip1l: F: 5'-AGGCCTCGGGATCCCAC
310 CTC-3', R: 5'-TCCAGTCCGCCGAGGGCGC-3'; circRNA-014740: F: 5'-AGACA
311 TTGATGACTGCTTATGC-3', R: 5'-CATAGCCCTGGTCACAAC-3'; circRNA-
312 16648: F: 5'-TTGGAGCTGCTGGCCCATCC-3', R: 5'-GCATTGTTGGTCCAACC
313 GGGTCT-3'; circRNA-005786: F: 5'-CTTGGCCTCTTCCTCCTTTT-3', R: 5'-TGG

314 GCCTCAGGAAGTAGAGA-3') via RT-qPCR with SYBR Premix ExTaqII (RR820A;
315 Takara Bio) according to the manufacturer's instructions. miRNA was reversely
316 transcribed at 16°C for 30min, and 37°C for 30min using specific primer 1224RT
317 (5'-TTAACTGGATACGAAGGGTCCGAACACCGGTCGTATCCAGTTAActccacc-
318 3'). RT-qPCR was performed using primer pairs 1224F: 5'-TGCGGGTGAGGAC
319 TGGGGAG-3' and 1224R: 5'-TACGAAGGGTCCGAACAC-3'. RNase R treatment
320 was performed as follows: 5 µg of total RNA was diluted in 20µl of water with 4U
321 RNase R/µg unless differently stated and 2µl of enzyme buffer (Epicenter), then
322 incubated 15min at 37°C and purified by phenol chloroform extraction. Reactions
323 were performed in triplicate. Gapdh (GF, 5'-GGTGAAGGTCGGTGTGAACG-3';
324 GR, 5'-CTCGCTCCTGGAAGATGGTG-3') was used as an internal control of
325 Ago2, Ubr5, Filip1l and and pre- circRNA-Filip1l. U6 snRNA (6F, 5'-CTCGCTTCG
326 GCAGCACATATACT-3'; 6R, 5'-ACGCTTCACGAATTTGCGTGTC-3') was used
327 as an internal control of miRNA-1224 and circRNA-Filip1l. The expression levels
328 of the target genes were quantified relative to Gapdh or U6 snRNA expression
329 (cycle threshold, CT) using the $2^{-\Delta\Delta CT}$ methods. Any value among triplicates that
330 had a marked difference (≥ 1.00) compared with the average of the other two was
331 omitted.

332

333 *Spinal neuron culture.* The primary culture of spinal neurons was carried out
334 according to the previous described ([Hugel and Schlichter, 2000](#)). Briefly, after

335 decapitation of 3- to 4-d-old mice under deep anesthesia, a laminectomy was
336 performed, and the third dorsal of the spinal cord was cut with a razor blade. The
337 tissue fragments were digested enzymatically for 45min at 37°C with papain (20
338 U/ml, Sigma, St. Louis, MO) in oxygenated divalent-free Earle's balanced salt
339 solution (EBSS, Life Technologies, Gaithersburg, MD). The enzymatic digestion
340 was stopped by adding 3ml EBSS containing bovine serum albumin (1 mg/ml;
341 Sigma), trypsin inhibitor (10 mg/ml; Sigma), and DNase (0.01%; Sigma), and a
342 mechanical dissociation were performed with a 1ml plastic pipette. The
343 homogenate was deposited on top of 4ml of a solution of composition similar to
344 that described above, except that the concentration of bovine serum albumin was
345 increased to 10 mg/ml. After centrifugation (5min at 500rpm), the supernatant was
346 removed and replaced with 5ml of culture medium the composition of which was
347 the following: MEM- α (Life Technologies), fetal calf serum (5% vol/vol; Life
348 Technologies), heat-inactivated horse serum (5% vol/vol; Life Technologies),
349 penicillin and streptomycin (50 IU/ml for each; Life Technologies), transferrin (10
350 mg/ml; Sigma), insulin (5 mg/ml; Sigma), putrescine (100nM; Sigma), and
351 progesterone (20nM; Sigma). After trituration with a fire-polished Pasteur pipette,
352 the cells were plated on 35mm collagen-coated plastic culture dishes in the
353 central compartment, which was delimited by a small (internal diameter 15mm)
354 circular glass ring. This ring was glued onto the bottom of the dish with paraffin
355 wax and could easily be removed before electrophysiological experiments.

356 Cultures were maintained in a water-saturated atmosphere (95% air, 5% CO₂) at
357 37°C until use (10–15 d). Two days after the cells were seeded; cytosine
358 arabinoside (10μM) was added to the culture medium for 24h to reduce glial
359 proliferation.

360

361 *Spinal astrocytes- and microglia cultures.*

362 The isolation of spinal astrocytes and microglia cells was carried out according to
363 the previous described (Monif et al., 2016) with few modifications. The third dorsal
364 of spinal cord from 3- to 4-d-old mice was cut, the tissue fragments were digested
365 enzymatically for 45 min at 37°C with trypsin (0.25 %, Gibco), and stopped by
366 adding equal volume DMEM with 10% FBS, then centrifuged at 1000g for 30s,
367 removed the supernatant, washed three times with DMEM with 10% FBS,
368 centrifuged at 1000g for 30s each time. The mixed cells were suspended by the
369 use of DMEM with 20% FBS, and filtered with 200 mesh sieve. The suspended
370 cells were plated into 75 cm² plate. After 30min, transferred the medium to the 75
371 cm² flask, cultured at 37°C for 7-10 days. To harvest the astrocytes, the flasks of
372 mixed glial cells were shaken at 220 rpm at 37°C overnight, discarded the
373 supernatant, the left was the astrocytes, and then added DMEM with 10% FBS,
374 and continued to culture at 37°C till to the cellular astrocyte density required. To
375 harvest microglial cells, the flasks of mixed glial cells were shaken at 150 rpm at
376 37°C for 4h, collected the supernatant containing the microglial cells to the new

377 plates, and continued to perform the culture at 37°C, till to the density of microglial
378 cells required

379

380 *Cellular fraction and RNA isolation.* PARIS™ Kit (Life Technologies, #AM1921)
381 was used to separately isolate nuclear and cytoplasmic RNA from cultured mouse
382 spinal neurons, following the manufacturer instructions.

383

384 *Immunofluorescence and fluorescence in situ hybridization.* The procedure was
385 performed as described in a previous study (Pan et al., 2014). In brief, spinal
386 cords were rapidly dissected from perfused mice and fixed with 4% PFA, then
387 cryoprotected in 30% sucrose. For fluorescence *in situ* hybridization (FISH) in
388 cultured cells, digoxin labeled circRNA-Filip1I probe (Dig-Filip1I, 5'-Dig-CGCCGG
389 GGAGGTGGGATCCCGA-Dig-3') or miRNA-1224 probe (Dig-1224, 5'-Dig-CTCC
390 ACCTCCCCAGTCCTCAC-Dig-3') was hybridize to spinal slices as instructed in
391 the FISH kit (Guangzhou Exon), and incubated with then fluorescent-conjugated
392 secondary anti-digoxin, and then after PBS wash 3 times FISH sections were
393 incubated with NeuN antibody (MAB377, Millipore), finally after PBS wash 3 times
394 incubated with fluorescent-conjugated secondary antibody (Alexa-594, Cell
395 Signaling Technology). After the sections were rinsed in 0.01M PBS, coverslips
396 were applied.

397

398 *Northern blot.* Northern blot was performed according to the previous described
399 (Legnini et al., 2017) with modified. Briefly, 10 μ g RNA was denatured with one
400 volume of glyoxal loading dye (Ambion) at 50°C for 30 min and loaded on 1.2%
401 agarose gel. Electrophoresis was carried out for 2.5h at 60V. RNA was transferred
402 on Hybond N⁺ membrane (GE Healthcare) by capillarity overnight in 10 \times SSC.
403 Transferred RNA was cross-linked with UV at 1200 \times 100 mJ/cm² and the
404 membrane was washed in 50mM Tris pH 8.0 at 45°C for 20min. Prehybridization
405 and hybridization were performed in Northern Max buffer (Ambion) at 68°C for
406 30min and overnight, respectively. 500ng of DIG-labeled probe in 10mL were
407 used for hybridization. The membrane was then washed with 2 \times SSC 0.1% SDS
408 twice 30min, then once 30min and once 1h with 0.2 \times SSC 0.1% SDS at
409 hybridization temperature. The membrane was the processed for DIG detection
410 (hybridization with anti-DIG antibody, washing and luminescence detection) with
411 the DIG luminescence detection kit (Roche), according to the manufacturer
412 instructions. DIG-labeled probes were produced by in vitro transcription with
413 DIG-RNA labeling kit (11175025910, Roche) of PCR templates produced with the
414 primers DFilip1IF (5'-AGGCCTCGGGATCCACCTC-3') and DT7-Filip1IR (5'-TA
415 ATACGACTCACTATAGGTCCAGTCCGCCGAGGGCGC-3'), used with mouse
416 cDNAs. circRNA transcription with T7 RNA polymerase (Promega) was carried
417 out at 37°C for 2h, then purified with Micro Bio-Spin 30 Chromatography Column
418 (732-6223, Bio-Rad).

419 *Synthetic anti-circRNA and circRNA mimics.* The anti-circRNA-Filip1I mimics and
420 linear circRNA-Filip1I were obtained by *in vitro* transcription from a
421 PCR-generated template, respectively with anti-circRNA-Filip1I primer pair
422 (DFilip1IF and DT7-Filip1IR) and linear circRNA-Filip1I primer pair (DT7- Filip1IF,
423 5'-TAATACGACTCACTATAGGGCTCCCCGGCGCGGG-3'/Filip1IR, 5'-GAG
424 GTGGGATCCCGAGGCCT-3' (using mouse cDNA as PCR template) in presence
425 of T7 polymerase (Promega) following the manufacturer's instructions, and
426 purified with Micro Bio-Spin 30 Chromatography Column (732-6223, Bio-Rad)
427 after DNase treatment. circRNA-Filip1I was synthesized using linear
428 circRNA-Filip1I according to the previous described (Legnini et al., 2017). A
429 phosphate group was then attached to the 5'-OH using ATP and T4
430 Polynucleotide kinase (BioLabs); the linear transcript carrying no 5'-phosphate
431 and 3'-OH ends was subjected to Ethanol precipitation in presence of 10mg of
432 glycogen (Roche). Ligase reaction was carried out in a final volume of 100µl,
433 incubating the linear transcript at 95°C for 2min followed by 5min at 75°C in
434 presence of 10% DMSO. T4 RNA Ligase (BioLabs), 1×T4 RNA Ligase Buffer,
435 10mM ATP and RNase inhibitor were then added and the reaction was carried out
436 at 16°C for 16h. The circularized RNA product was separated and purified from
437 the linear transcript by polyacrylamide gel electrophoresis. Thirty nanograms of
438 both circular and linear transcripts were subjected to RNase R treatment followed
439 by qRT-PCR to assess the circularity of the gel-purified RNA molecules.

440 *Plasmid construction.* All constructs were produced by the use of standard
441 molecular methods and confirmed by DNA sequencing. To construct
442 circRNA-Filip1l, miRNA-1224, and Ago2 overexpression vectors (OE): one insert
443 prepared by PCR using primer pairs [circRNA-Filip1l OE: PWFilpF, 5'-ACGCTC
444 GAGAGTGGCCCACTAGGCACTC-3' (XhoI)/PWFilpR, 5'-GGCGTTTAAACAAAC
445 AATAAGTCTGGGAGAG-3' (PmeI); miRNA-1224 OE: PW1224F, 5'-CGGGATCC
446 GAGCCCATATCTCCTACTGG-3' (BamHI)/PW1224R, 5'-AATACGCGTTTCGACA
447 CAGGCGTTCTTGAG-3' (MluI); and Ago2 OE: PW-Ago2F, 5'-AATGGATCCATG
448 TACTCGGGAGCCGGCCC-3' (BamHI)/PW-Ago2R, 5'-AATACGCGTTCAAGCAA
449 AGTACATGGTGCGC-3' (MluI)] and PWPXLvector were digested by
450 corresponding double restriction endonucleases (NEB), and then ligated with T4
451 ligase. To construct circRNA-Filip1l overexpression vectors in DNA3.1 plasmid:
452 one insert from PCR with PCR pair [5'-ACGAAGCTTAGCCTGAGTTTGCCATCT
453 TG-3' (HindIII) and 5'-ACGCTCGAGTCAAAGAACTAACGGCAAC-3' (XhoI)] and
454 the digested cDNA3.1 vector, and then ligated with T4 ligase. To construct
455 circRNA-Filip1l, miRNA-1224 and Ubr5 knockdown vector (KD), LV-anti-Filip1lF
456 [5'-P-CGCGCCACCTCCCTCCCCGGCGCGGGCGAGACGGGCCGGTG
457 G-3' (MluI)] and LV-anti-Filip1lR [5'-P-CGCCACCGGCCCGTCTCGCCCGCCG
458 CGCCGGGAGGGAGGTGGG-3' (ClaI)], or PLV-1224F [5'-P-CGCGGTGAGGA
459 CACCGAGGTGGAGtagcGTGAGGACACCGAGGTGGAG-3' (MluI)] and PLV-
460 1224R [5'-P-CGCTCCACCTCGGTGTCTCACgctaCTCCACCTCGGTGTCCTC

461 AC-3'(ClaI)] or PLV-Ubr5F [5'-P-CGCGGAATGTACTGGAGCAGGCTACTATTCG
462 AAAATAGTAGCCTGCTCCAGTACATTC-3' (MluI)] and PLV-Ubr5R [5'-P-CGGA
463 ATGTACTGGAGCAGGCTACTATTTTCGAATAGTAGCCTGCTCCAGTACATTCC
464 G-3' (ClaI)] was annealed and ligated to the digested PLVTHM vector,
465 respectively.

466

467 *Lentivirus production and verification.* The constructed core plasmid (16 μ g) and
468 two envelope plasmids, PSPAX2 (12 μ g) and PMD2G (4.8 μ g), were
469 co-transfected into HEK293T cells in a 6-well plate according to manufacturer
470 instructions of Lipofectamine 2000 (11668-027, Invitrogen). The supernatant was
471 collected at 48h after transfection, and concentrated by using a Centricon Plus-70
472 filter unit (UFC910096, Millipore). Lentivirus with titers 10^8 TU/ml was used in the
473 experiment. The assays of lentivirus *in vitro* and *in vivo* infection were performed
474 according to previous study (Pan et al., 2014). Briefly, 20 μ l lentivirus and 1.5 μ l
475 polybrene (1.4 μ g/ μ l; H9268, Sigma-Aldrich) were added in a 24-well plate
476 containing 1×10^5 HEK293T cells and DMEM without FBS; after 24h, the
477 transfection medium was replaced with 500 μ l fresh complete medium containing
478 10% FBS; cells were collected at 48h after culture.

479 For *in vivo* verification of lentivirus, daily intrathecal injections of lentivirus or
480 vector (1 μ l) were performed for 2 consecutive days in naïve or pain mice, then

481 collected samples day 3 after the first injection. Otherwise please see the
482 specified injection time points detailed in corresponded figure legend.

483

484 *SiRNA, mimics, inhibitor, and lentivirus delivery.* Injections were performed by
485 holding the mouse firmly by the pelvic girdle and inserting a 30-gauge needle
486 attached to a 25- μ l microsyringe between L5 and L6 vertebrae. Proper insertion of
487 the needle into the subarachnoid space was verified by a slight flick of the tail after
488 a sudden advancement of the needle. Injections of 5 μ l of 20 μ M siRNAs, mimics
489 and inhibitor for circRNA-Filip1l (5'-GCGCCGGGAGGUGGAGCACGAGC-3'),
490 Ago2 (sense: 5'-GCGCCGGGAGGCGGAGCCACGAGCTT-3', antisense: 5'-G
491 CTCGTGGCTCCGCCTCCCCGGCGCTT-3'), Ubr5 (sense: 5'-GAAUGUACUG
492 GAGCAGGCUACUATT-3', antisense: 5'-UAGUAGCCUGCUCCAGUACAUUCT
493 T-3'), or 1 μ l Lentivirus were performed daily for 3 days in a double blind trial
494 fashion. Knockdown via Ago2-siRNA, ubr5-siRNA, PLV-Ubr5 was confirmed with
495 RT-qPCR from samples of the ipsilateral dorsal spinal cord taken 72h after the
496 last injection. Animals receiving intrathecal injections of scrambled siRNA or an
497 empty vector were used as control groups.

498

499 *Construction of reporter vector.* The defined region of Ubr5 promoter was
500 amplified from mouse genomic DNA using primer pairs (G6-U5F, 5'-ACGCTCGA
501 GCAGGCTGCGAGACGGAGAAAC-3' and G6-U5R, 5'-AATAAGCTTCAGCGGG

502 TGGACCACGAAAT-3'), and cloned into pGL6 plasmid (Beyotime) via XhoI and
503 HindIII digestion. Empty pGL6 vector was used as control plasmid. To construct
504 the psiCK-wt-Filip1I or psiCK-mut-Filip1I reporter vector, psiCK-wtF [5'-P-
505 TCGAGTCCTAACGCGTACGCTCGTGCTCCACCTCCCCGGCGCGGGGCG
506 AGACGGGC-3' (XhoI)] (Underlined presents the reverse complementary
507 fragment in pre-circRNA-Filip1I to miRNA-1224) and psiCK-wtR [5'-P-GGCCGC
508 CCGTCTCGCCCGCCGCGCCGGGGAGGTGGAGCACGAGCGTACGCGTTAG
509 GAC-3' (NotI)], or psiCK-mutF [5'-P-TCGAGTCCTAACGCGTACGCTCGTGCTA
510 ATCAGTTCCGGCGCGGGCGGGCGAGACGGGC-3' (XhoI)] and psiCK-mutR [5'-
511 P-GGCCGCCCCGTCTCGCCCGCCGCGCCGGAAGTATTAGCACGAGCGTAC
512 GCGTTAGGAC-3' (NotI)], were annealed and ligated to the digested psiCHECK2
513 vector, respectively.

514

515 *Single cell RT-PCR.* Single-cell RT-PCR for spinal neurons was performed as
516 described previously with few modifications (Jiang et al., 2016). Briefly, the
517 contents of dissociated spinal neurons from CFA mice were harvested into patch
518 pipettes with tip, placed gently into reaction tubes with Dnase I at 37°C for 30min,
519 and heated to 80°C for 5min to remove genomic DNA. Reverse transcriptase
520 (SuperScript III Platinum; Invitrogen) and specific reverse outer primer or 1224-RT
521 was added, the sample was incubated at 50°C for 50min, and the reaction was
522 terminated at 70°C for 15min. The cDNA products were used in gene-specific

523 nested PCR. The first-round PCR was performed with the outer primer pair (outF
524 and outR) in the FastStart universal SYBR green master kit (Roche, Switzerland).
525 PCR conditions were as follows: 1 cycle of 3min at 94°C; 5 cycles of 15s at 95°C
526 and 5min at 56°C, 30s at 72°C ; then 20 cycles of 15s at 95°C and 15s at 60°C,
527 30s at 72°C, and 1 cycle of 10min at 72°C. The second round of PCR was carried
528 out using 0.5µl of the first PCR product as the template and with inner PCR
529 primers (inF and inR). The amplification: 1 cycle of 3 min at 94°C; 35 cycles of 15s
530 at 95°C and 15s at 60°C, 30s at 72°C, and 1 cycle of 3min at 72°C. A negative
531 control was obtained from pipettes that were submerged in the bath solution only.
532 Gapdh was used as the reference gene. The primers are shown as the following:
533 circRNA-Filip1l: outF/inF, 5'-ACTGGAGAGGCCTCGGGATC-3'; outR, 5'-CGCCG
534 AGGGCGCACCACC-3'; inR, 5'-CGCACCACCGGCCCGTGCC-3'. miRNA-1224:
535 RT, and outF/outR same as 1224RT, and 1224F/1224R above, respectively; inF,
536 5'-GGGTGAGGACTGGGGAG-3'; inR, 5'-AAGGGTCCGAACACCGG-3'. Ago2:
537 outF, 5'-AGTTTGACTTCTACCTGTGCA-3'; outR, 5'-TGTGTCCTGGTGGACCT
538 GGA-3'. inF/inR same as Ago2 F/R above. Ubr5: outF, 5'-AGAAGCAATTGCCG
539 TGACAAT-3', outR, 5'-TGCTTGCCTGATCTGATGAC-3'. inF, 5'-TGAGGTTTCT
540 ACGATCTGTGGC-3'; inR, 5'-AAACACACGTTTGCATTTTCCA-3'. NeuN: outF,
541 5'-AGACAGACAACCAGCAACTC-3'; outR, 5'-CTGTTCTACCACAGGGTTTAG-3'.
542 inF, 5'-ACGATCGTAGAGGGACG-3'; inR, 5'-TTGGCATATGGGTTCCCAGG-3'.
543 Gapdh: outF, 5'-AGGTTTCATCAGGTAAACTCAG-3'; outR, 5'-ACCAGTAGAC

544 TCCACGACAT-3'. inF, ACCAGGGCTGCCATTTGCA; inR, 5'-CTCGCTCCTGGA
545 AGATGGTG-3'.

546

547 *Luciferase reporter assay.* HEK293T cells were cultured in DMEM with 10% FBS.
548 HEK293T cells were seeded at 1×10^5 cells per 24-well. Identification of target was
549 performed by transfecting reporter plasmids (50ng) and DNA3.1-Filip1I (80ng) or
550 Lenti-Ago2 vector (80ng), or miRNA-1224 mimics (80ng) or inhibitor (50ng) into
551 HEK293T cells using Lipofectamine 2000 (11668-027, Invitrogen) in a 24-well
552 plate. Cell lysates were prepared and subjected to luciferase assays using the
553 Double luciferase reporter kit (E1910, Promega) at 48h after transfection
554 according to the manufacturer's instruction. pRL-TK plasmid was used as an
555 internal control (Promega).

556

557 *RNA-binding protein immunoprecipitation (RIP).* Immunoprecipitations were
558 performed using Magna RIP™ RNA-Binding Protein Immunoprecipitation Kit
559 (17-700, Millipore). Briefly, spinal cord was harvested and placed in ice-cold PBS,
560 then homogenized and centrifuged 1500rpm for 5min at 4°C, obtained the
561 supernatant. Added 50μl of magnetic beads and ~5μg of the antibody of Ago2
562 (ab186733, Abcam) in each tube, incubated with rotation for 30min at room
563 temperature. Then, re-suspend the mixture by RIP immunoprecipitation buffer
564 and added the tissue supernatant, incubated with rotation for overnight at 4°C and

565 pull down the RNA on the magnetic rack. Finally, digested the protein with
566 proteinase K and extracted RNA for PT-qPCR.

567

568 *RNA-RNA in vivo precipitation (RRIP)*. According to the previously described (Su
569 et al., 2015) with modification, biotin-labeled miRNA-1224 probe (Bio-1224, 5'-CT
570 CCACCTCCCCAGTCCTCAC-Bio-3') was used to perform the RRIP experiment
571 assay. Spinal cord was harvested 24h after intrathecal injection of Bio-1224 (5 μ l,
572 20 μ M) and fixed by 2.5% formaldehyde for 10min, lysed and sonicated. After
573 centrifugation, 50 μ l of the supernatant was retained as input and the remaining
574 part was incubated with Dynabeads M-280 Streptavidin (11205D, Thermo Fisher
575 Scientific) mixture over night at 4°C. Next day, beads-probes-RNAs mixture was
576 washed and incubated with 200 μ l lysis buffer and proteinase K to reverse the
577 formaldehyde crosslinking. Finally, the mixture was added with TRizol for RNA
578 extraction and detection.

579

580 *Western blot analysis*. Proteins (20 to 50 μ g/sample) were separated by 10% SDS
581 polyacrylamide gel electrophoresis and transferred onto nitrocellulose
582 membranes, and incubated simultaneously at 4°C overnight in the corresponding
583 antibodies against: Ago2 (1:500, ab186733; Abcam), Ubr5 (1:1000, 65344; Cell
584 signaling), or control Tubulin β polyclonal antibody (1:5000; AP0064; bioworld).
585 The membranes were then washed twice in tris-buffered saline with Tween-20 at

586 room temperature for 10min, incubated with HRP-labeled Goat Anti-Rabbit IgG
587 (1:1000; A0208; Beyotime) at room temperature for 1h, and washed twice again in
588 Tris-buffered saline with Tween-20 at room temperature for 10min. The immune
589 complexes were detected with an NBT/BCIP (nitro blue tetrazolium/
590 5-bromo-4-chloro-3-indolyl-phosphate) assay kit (72091; Sigma-Aldrich). Band
591 analyses were performed in ImageJ software, with the intensities of the target
592 signals normalized to those of β -actin for statistical analyses.

593

594 *Statistical analysis.* All data were presented as mean values \pm SEM. The data
595 were statistically analyzed with a one-way or two-way ANOVA or paired or
596 unpaired Student's t test. When ANOVA showed a significant difference, pairwise
597 comparisons between means were tested by the post hoc Tukey method.
598 Statistical analyses were performed with Prism (GraphPad 5.00, USA). $p < 0.05$
599 was considered statistically significance in all analyses.

600

601

602

603

604

605

606

607 **Results**

608

609 **Profiling of spinal circRNAs in CFA-induced chronic inflammatory pain**

610 The abundance of circRNAs in the CNS suggests its potential roles in dynamic
611 regulation of structure and function of the CNS (Shao and Chen, 2016). To identify
612 spinal circRNAs involved in chronic inflammation pain, we analyzed the circRNA
613 expression profiling from ipsilateral dorsal spinal cord of chronic inflammation pain
614 mice and control mice. 16 up-regulated and 34 down-regulated circRNAs with >
615 2.0 fold difference were obtained from 1099 candidates (Fig. 1A).
616 CircRNA-005252 with most significant difference, and other three randomly
617 selected circRNAs, including 1 up-regulated and 2 down-regulated in microarray
618 analysis, were further confirmed by qRT-PCR (Fig. 1B). CircRNA-005252 (namely
619 circRNA-Filip1l or mmu_circ_0000691 in circbase database (Memczak et al., 2013))
620 --- was up-regulated by 2.8 fold. The further analysis showed that circRNA-Filip1l
621 was located on Chr16: 57391624 - 57391694 (+), and back spliced by intron 1 of
622 Filip1l, the distinct product of the expected size was amplified using
623 outward-facing primers and confirmed by Sanger sequencing (Fig. 1C). We then
624 investigated the stability and localization of circRNA-Filip1l in spinal cells.
625 Resistance to digestion with RNase R exonuclease showed that circRNA-Filip1l
626 was resistant to RNase R digestion, whereas linear Filip1l mRNA was easily
627 degraded; further confirming that circRNA-Filip1l specie was circular in form (Fig.

628 1D). Northern blot assay verified the size of circRNA-Filip1l expected in spinal
629 RNA of adult mouse (Fig. 1E). Furthermore, to clarify the distribution of
630 circRNA-Filip1l in nucleus and cytoplasm, we separated the nucleus RNA and
631 cytoplasmic RNA from *in vitro* cultured spinal neurons to detect the content of
632 circRNA-Filip1l. RT-qPCR showed that the circRNA-Filip1l was localized in both
633 nucleus and cytoplasm fraction (Fig. 1F). Fluorescence *in situ* hybridization
634 further confirmed its localization in nucleus and cytoplasm of spinal neurons (Fig.
635 1G). These findings suggest that circRNA-Filip1l is an abundant and stable
636 circular noncoding RNA expressed in spinal cord of mice.

637

638 **Expression patterns of spinal circRNA-Filip1l underlying chronic pain**

639 To uncover a temporal expression pattern of circRNA-Filip1l in spinal cord in
640 chronic inflammation pain mice, we detected expression level of circRNA-Filip1l in
641 the spinal dorsal or ventral horn of mice from hour 2 to day 14 after subcutaneous
642 injection of CFA. RT-qPCR results showed that circRNA-Filip1l expression in the
643 spinal dorsal horn was not altered in the acute phase (2 h) after CFA injection,
644 however, was increased by 75% day 1, reached a peak (180%) day 3, diminished
645 day 7, and then returned to almost basal level day 14 after CFA injection (Fig. 2A).
646 The circRNA-Filip1l level in the ventral horn of spinal cord was increased merely
647 by 60 % day 3 and 53% day 7, but had no change at the other time points after
648 CFA injection (Fig. 2B). Furthermore, we found that the expression of

649 circRNA-Filip1l in the contralateral spinal dorsal horn (Fig. 2C) and ipsilateral
650 DRG (Fig. 2D) was not altered from hour 2 to day 14 after CFA injection. These
651 results suggest that ipsilateral spinal dorsal horn is a major region contributing to
652 the increase of circRNA-Filip1l in chronic inflammation pain. This increase trend of
653 spinal circRNA-Filip1l expression related to chronic pain also was found in
654 ipsilateral spinal dorsal horn of CCI mice (another chronic pain model) day 3, 7
655 and 14 after surgery (Fig. 2E), but not observed in the ipsilateral DRG of CCI mice
656 (Fig. 2F). These data indicate the possible involvement of spinal circRNA-Filip1l
657 not only in chronic inflammatory pain but also in chronic neuropathic pain. Then,
658 we characterized the differential spatial patterns of expression of spinal
659 circRNA-Filip1l by combining FISH and cell-type-specific immunofluorescence
660 staining *in vivo*. We observed that circRNA-Filip1l was co-localized with NeuN, a
661 neuronal maker, in spinal cord (Fig. 2G). To further measure the expression level
662 of circRNA-Filip1l in spinal neurons and non-neurons, we analyzed its content in
663 the cultured spinal neurons and glial cells including astrocytes and microglial cells.
664 As shown in Fig. 2H, circRNA-Filip1l in neurons was 7.8 fold as that in microglial
665 cells, and 6.2 fold as that in astrocyte cells, indicating circRNA-Filip1l is mainly
666 expressed in spinal neuron cells. Since the cultured neurons can be depolarized
667 with high concentration KCl to mimic sensitized *in vivo* neurons by nociceptive
668 response (Yang et al., 2015). We treated the cultured spinal neurons with 50 mM
669 KCl for 12 h, and found that circRNA-Filip1l was significantly increased by this

670 treatment (Fig. 2I), supporting a consistent change trend of circRNA-Filip1l
671 expression between the spinal neurons of CFA-treated mice and KCI-treated
672 spinal neurons *in vitro*. In addition, single-cell RT-PCR showed that five of six
673 spinal neurons from CFA mice expressed circRNA-Filip1l (Fig. 2J), further
674 confirming that the majority of spinal neurons express circRNA-Filip1l. Collectively,
675 these results suggest that spinal circRNA-Filip1l is increased under chronic pain
676 conditions.

677

678 **Regulation of nociception by spinal circRNA-Filip1l**

679 To further evaluate the therapeutic potential of spinal circRNA-Filip1l blockade in
680 the relief of nociception response, we used the linear specific antisense of
681 circRNA-Filip1l, including one exogenously synthesized anti-Filip1l by the use of
682 *in vitro* T7 transcription, an antisense RNA of cirRNA-Filip1l that can prevent it
683 from binding to its target gene; and another endogenous PLV-anti-Filip1l with GFP
684 label *in vivo* expressed by lentivirus to block spinal circRNA-Filip1l in CFA mice.
685 The analysis of GFP fluorescence intensity showed that PLV-anti-Filip1l mainly
686 expressed in spinal neurons of naïve mice day 3 after 2 consecutive days'
687 intrathecal injection (Fig. 3A). Before the measure of nociceptive behavior, to
688 exclude the possibility that the observed effects were affected by
689 locomotor impairment, we observed the locomotor function in mice by testing their
690 grasping reflex, placing reflex and righting reflex. Results showed that blocking

691 circRNA-Filip1l with anti-Filip1l or PLV-anti-Filip1l did not influence the locomotor
692 function of the mice (Table 1.). Thermal and mechanical nociceptive responses
693 were attenuated hour 24 after intrathecal injections of anti-Filip1l, but not
694 scrambled control in CFA mice, these alleviative effects lasted at least 2 days (Fig.
695 3B). The anti-nociceptive effects of PLV-anti-Filip1l were also observed day 2 after
696 intrathecal injection of PLV-anti-Filip1l in CFA mice (Fig. 3C), the effects had been
697 maintained during the entire period of observation. To further explore the role of
698 spinal circRNA-Filip1l in nociceptive regulation, then, we examined whether
699 circRNA-Filip1l overexpression mimicks the nociception-like behavior in naïve
700 mice. To this end, two manipulating tools were employed --- exogenous
701 circRNA-Filip1l mimics synthesized through cyclizing the linear circRNA-Filip1l
702 from *in vitro* T7 transcription according to the previous described (Legnini et al.,
703 2017), and endogenous Lenti-Filip1l lentivirus --- to overexpress the
704 circRNA-Filip1l in spinal cord of mice. Validation experiments showed that spinal
705 circRNA-Filip1l expression in naïve mice were up-regulated by 157% day 2 after
706 treatment with circRNA-Filip1l mimics and by 155% day 3 after Lenti-Filip1l
707 treatment, respectively (Fig. 3D, E). Similarly, Lenti-Filip1l with GFP label mainly
708 expressed in spinal neurons of naïve mice day 3 after 2 consecutive days'
709 intrathecal injection (Fig. 3F). Locomotor impairment was not found after
710 overexpression of spinal circRNA-Filip1l by the use of circRNA-Filip1l mimics or
711 Lenti-Filip1l (Table 1.). However, the intrathecal injections of circRNA-Filip1l

712 mimics or Lenti-Filip1l for 2 or 3 consecutive days, but not scrambled control or
713 empty vector, significantly produced a nociception-like behavior as evidenced by
714 a decrease threshold of mechanical or thermal stimulation (Fig. 3G, H). Together,
715 these findings establish that spinal circRNA-Filip1l plays an essential role in
716 physical and pathological nociceptive regulation.

717

718 **MiRNA-1224 is an upstream regulator of circRNA-Filip1l**

719 How is spinal circRNA-Filip1l up-regulated under chronic inflammatory pain
720 conditions? Data from previous study suggest that miRNAs modulate the
721 circRNAs expression via binding to the circRNA in cell nucleus (Hansen et al.,
722 2011). Through search in mirbase database using sequence of circRNA-Filip1l or
723 its precursor (pre-circRNA-Filip1l), we predicted possible miRNAs with the binding
724 sites to circRNA-Filip1l or pre-circRNA-Filip1l. We found that 14nt fragment in
725 miRNA-1224 was complementary to pre-circRNA-Filip1l region spanning its 5'
726 junction flank (Fig. 4A). Due to the location of pre-circRNA-Filip1l in spinal nucleus
727 fraction, we supposed that miRNA-1224, as an upstream regulator, may be
728 involved in the modulation of circRNA-Filip1l expression via the mediation of its
729 cleavage. To confirm the existence of miRNA-1224 in spinal nucleus, we detected
730 miRNA-1224 content in both nucleus and cytoplasm of spinal neuron cultured.
731 MiRNA-1224 was mainly located in nucleus, and its level in nucleus was 3.8-fold
732 higher than that in cytoplasm (Fig. 4B). FISH further confirmed the preferential

733 localization of miRNA-1224 in nucleus of spinal neurons (Fig. 4C). Furthermore,
734 spinal miRNA-1224 expression was time-dependently decreased from hour 2 to
735 day 7 after CFA injection (Fig. 4D). Co-staining confirmed that miRNA-1224 was
736 spatially localized in the spinal neurons, and markedly increased under
737 CFA-induced inflammatory pain conditions (Fig. 4E).

738 To experimentally validate the *in silicon* prediction of miRNA-1224 regulating
739 circRNA-Filip1l expression, we cloned a bound fragment of pre-circRNA-Filip1l
740 by miRNA-1224 into psiCHECK reporter vector and detected the effect of
741 miRNA-1224 on the activities of the reporter in HEK293T cells. Co-transfection of
742 miRNA-1224 mimics with the reporter psiCK-wt-pre-Filip1l decreased luciferase
743 activities by 39% compared with mutated psiCK-mut-pre-Filip1l vector. Contrarily,
744 miRNA-1224 inhibitor elevated luciferase activities by 52% in psiCK-wt-pre-Filip1l,
745 but not in psiCK-mut-pre-Filip1l (Fig. 4F). These data indicate that miRNA-1224 *in*
746 *vitro* negatively regulates the expression of circRNA-Filip1l. To seek to determine
747 whether miRNA-1224 regulates circRNA-Filip1l expression *in vivo* via binding to
748 pre-circRNA-Filip1l, we firstly examined the binding capacity of miRNA-1224 to
749 pre-circRNA-Filip1l. We intrathecally injected bio-labeled miRNA-1224 probes into
750 control and CFA mice, and then tested the content of pre-circRNA-Filip1l
751 pull-down hour 24 after injection. RT-qPCR showed that pre-circRNA-Filip1l was
752 pull down by miRNA-1224 probes, and was increased in spinal cord of CFA mice,
753 compared with saline group (Fig. 4G), confirming the binding ability of

754 miRNA-1224 to the pre-circRNA-Filip1l *in vivo*. Next, we further determined if
755 miRNA-1224 can regulate circRNA-Filip1l expression by targeting
756 pre-circRNA-Filip1l. Here, two tools including miRNA-1224 mimics and Lenti-1224
757 were synthesized or constructed as the described methods previously (Pan et al.,
758 2014) to up-regulate the expression of miRNA-1224. Their work efficiencies were
759 validated *in vitro* and *in vivo*. As shown in Figure 5A, HEK-293 cells transfected
760 with miRNA-1224 mimics or Lenti-1224, but not scrambled or empty vector,
761 displayed the increased miRNA-1224 by 118% or 189%, respectively (Fig. 4H).
762 The expression of miRNA-1224 was up-regulated by 79% hour 48 after 2
763 consecutive days' miRNA-1224 mimics injection, or by 110% hour 72 after 2
764 consecutive days' Lenti-1224 injection in naïve mice and CFA mice (Fig. 4I).
765 Furthermore, we found that overexpressing miRNA-1224 with miRNA-1224
766 mimics or Lenti-1224 in spinal cord of CFA mice blocked the CFA-evoked
767 increase in spinal circRNA-Filip1l expression compared to the scrambled or
768 Lenti-vector group (Fig. 4J), however, did not change the increase in spinal
769 pre-circRNA-Filip1l of CFA mice (Fig. 4K). In contrast, blocking miRNA-1224 with
770 its inhibitor or PLV-1224 led to the increase of circRNA-Filip1l level (Fig. 4L), but
771 unaltered the pre-circRNA-Filip1l level in spinal cord of naïve mice (Fig. 4M).
772 Together, these *in vitro* and *in vivo* results indicate miRNA-1224 regulates
773 expression of circRNA-Filip1l, but not pre-circRNA-Filip1l.

774

775 **MiRNA-1224 regulates nociception by mediation of circRNA-Filip11**

776 Our results indicate that miRNA-1224 modulates spinal circRNA-Filip11
777 expression under chronic inflammatory pain conditions. Therefore, spinal
778 miRNA-1224 may also participate in the process of nociception regulation. Prior to
779 pain behavior evaluation, we examined the effect of miRNA-1224 regulation tools
780 on locomotor function. The reflex tests showed that miRNA-1224 overexpression
781 with miRNA-1224 mimics or Lenti-1224 did not affect the locomotor function
782 (Table 1.). However, CFA-induced thermal and mechanical nociceptive responses
783 were attenuated hour 48 after the intrathecal injection of miRNA-1224 mimics (Fig.
784 5A) or hour 72 after intrathecal injection of Lenti-1224 (Fig. 5B). Anti-nociceptive
785 effect was undetected after the injection of scramble (Fig. 5A) or empty vector (Fig.
786 5B). We also observed that pre-treatment with Lenti-1224, not empty vector, (*i.t.*
787 injection of Lenti-1224 or empty vector for 2 consecutive days before CFA
788 injection) significantly prevented CFA-induced nociceptive responses (Fig. 5C).
789 Next, we tested whether knockdown of spinal miRNA-1224 in naïve mice can
790 induce the nociception-like behavior. The reflex tests confirmed no impairment of
791 locomotor function after down-regulation of spinal miRNA-1224 expression via
792 intrathecally injecting miRNA-1224 inhibitor or PLV-1224 or their negative controls
793 for 2 consecutive days in naïve mice (Table 1.). While, the same treatment with
794 miRNA-1224 inhibitor (Fig. 5D) or PLV-1224 (Fig. 5E), but not scramble or empty
795 vector, significantly produced nociceptive responses as evidenced by a decrease

796 of thermal and mechanical pain threshold (Fig. 5D, E). These findings suggest
797 that spinal miRNA-1224 is involved in the process of nociceptive response. Finally,
798 we checked whether miRNA-1224 regulates pain behavior through the mediation
799 of circRNA-Filip1l. Naïve mice were pre-treatment or post-treatment with
800 miRNA-1224 inhibitor or lentivirus to knockdown their spinal miRNA-1224 before
801 or after intrathecal injection of anti-Filip1l, respectively, and then their nociceptive
802 responses were measured. We observed that knockdown of circRNA-Filip1l
803 significantly inhibited or reversed nociceptive responses induced by the block of
804 miRNA-1224 with lentivirus (Fig. 5F) or inhibitor (Fig. 5G), suggesting that
805 circRNA-Filip1l mediates the regulation of nociception by miRNA-1224. Taken
806 together, these findings indicate that spinal miRNA-1224 regulates nociception via
807 negatively targeting circR-Filip1l.

808

809 **Ago2-mediated cleavage of pre-circRNA-Filip1l bound by miRNA-1224**

810 To date, the modulatory mechanism of circRNA expression is poorly understood.
811 In recent study, it has been demonstrated that miRNA-671 directs cleavage of a
812 circular antisense transcript of CDR1 in an Ago2-slicer-dependent manner
813 (Hansen et al., 2011). Therefore, we hypothesized that miRNA-1224 mediates the
814 cleavage of pre-circRNA-Filip1l in Ago2-dependent manner to regulate the
815 content of mature circRNA-Filip1l. To test the point, firstly, we co-transfected Ago2
816 overexpression plasmid (Lenti-Ago2) and miRNA-1224 mimics with wild reporter

817 psiCK-wt-pre-Filip1l or mutation reporter psiCK-mut-pre-Filip1l in HEK293T cells.
818 The transfection of miRNA-1224 mimics reduced the luciferase activities in
819 psiCK-wt-pre-Filip1l group, compared with psiCK-mut-pre-Filip1l group; the
820 overexpression of Ago2 further decreased the luciferase activities (Fig. 6A),
821 suggesting the overexpression of Ago2 inhibits the activity of pre-circRNA-Filip1l
822 expression. We further examined whether Ago2 can combine to pre-cirRNA-
823 Filip1l and miRNA-1224. We used Ago2 antibody to pull down spinal
824 pre-circRNA-Filip1l and miRNA-1224. RNA immunoprecipitation (RIP) showed
825 that both pre-circRNA-Filip1l and miRNA-1224 were pulled down by Ago2
826 antibody, and the harvested amounts were decreased in CFA mice compared with
827 saline group (Fig. 6B). Next, we investigated whether Ago2 is involved in
828 regulation of circRNA-Filip1l and pre-circRNA-Filip1l expression. Due to the
829 reduced level of spinal Ago2 protein (Fig. 6C) day 3 after CFA injection,
830 Lenti-Ago2 or Ago2 protein were intrathecally injected into CFA mice to
831 overexpress Ago2; as well as PLV-Ago2 or Ago2-siRNA into naïve mice to
832 knockdown Ago2 expression, then the effect of Ago2 on expression of
833 circRNA-Filip1l and pre-circRNA-Filip1l were evaluated. The tools of manipulating
834 Ago2 were firstly validated. Ago2 protein was increased by 54% day 2 after
835 intrathecal injection of Lenti-Ago2 in saline group mice; the decreased Ago2
836 expression was reversed day 3 after the same treatment in CFA mice (Fig. 6C),
837 respectively. Ago2 expression was reduced by 41.2% or 39.3% day 2 after

838 intrathecal injection of Ago2-siRNA or day 3 after PLV-Ago2 injection in naïve
839 mice, respectively (Fig. 6D). As expected, compared with the PBS or vector
840 control group, the intrathecal injections of Ago2 protein or Lenti-Ago2 abolished
841 the increase of spinal circRNA-Filip1l (Fig. 6E), but did not change the
842 pre-circRNA-Filip1l level (Fig. 6F) in CFA mice. Intrathecal injections of
843 Ago2-siRNA or PLV-Ago2 significantly elevated the expression of spinal
844 circRNA-Filip1l (Fig. 6G), but not pre-circRNA-Filip1l level in naïve mice (Fig. 6H).
845 These results suggest that Ago2 affects the expression of circRNA-Filip1l, but not
846 pre-circRNA-Filip1l. Finally, we wanted to know whether mice receiving the
847 intrathecal injections of manipulation tools of Ago2 display behavioral changes in
848 nociceptive thresholds. We observed that the injections of Ago2 protein (Fig. 6I) or
849 Lenti-Ago2 (Fig. 6J), but not of PBS (Fig. 6I) or Lenti-vector (Fig. 6J), significantly
850 blunted the thermal and mechanical nociception, respectively. On the contrary,
851 injections of Ago2-siRNA (Fig. 6K) or PLV-Ago2 (Fig. 6L), but not of scramble (Fig.
852 6K) or vector (Fig. 6L), produced nociceptive responses. To further examine
853 whether Ago2 regulates nociception via the mediation of circRNA-Filip1l or
854 miRNA-1224, we evaluated the effect of blocking circRNA-Filip1l on nociception
855 induced by knockdown of Ago2. As expected, blockage of circRNA-Filip1l by
856 intrathecal pre-injection of anti-Filip1l prevented nociceptive responses induced
857 by Ago2 down-regulation in naïve mice (Fig. 6M). However, overexpression of
858 spinal miRNA-1224 with Lenti-1224 did not prevent nociception induced by

859 Ago2-siRNA in naïve mice (Fig. 6N), indicating Ago2 regulates nociceptive
860 responses via circRNA-Filip1l, but not miRNA-1224. Collectively, these findings
861 suggest that Ago2 is involved in regulation of physical and pathological
862 nociception via miRNA-1224-dependent cleavage in circRNA-Filip1l.

863

864 **CircRNA-Filip1l regulates nociception via targeting Ubr5**

865 Many recent studies (Li et al., 2015; Long et al., 2017) have shown that nucleus
866 circRNAs contribute to gene transcription via recruiting the RNA polymerase II.
867 Therefore, we wanted to know what are the downstream of circRNA-Filip1l
868 underlying regulation of nociception. Firstly, we performed an *in silicon* target
869 prediction using linear sequence of circRNA-Filip1l in BLAST program of NCBI. A
870 total of 42 genes were predicted as the potential targets of circRNA-Filip1l. Some
871 (e.g., Rn28s1, LOC105242388) are the ribosomal RNA or noncoding RNA, others
872 are the unreported pain-related genes such as Atxn2, Pwwp2a, Plxdc2 and Ubr5.
873 Among them, ubiquitin protein ligase E3 component n-recogin 5 (Ubr5) can
874 regulate the neuronal plasticity through activating the NMDA receptor in CNS, and
875 is implicated in the pathologic process of central neural system diseases such as
876 depression and epilepsy through ubiquitination of modification (Kato et al., 2012;
877 Christensen et al., 2013). In Ubr5 gene, the specific region near transcription start
878 site (TSS) of Ubr5 (+221 - +242, TSS as +1) was found to be bound by
879 circRNA-Filip1l (+25 - +4, 5' junction as +1) (Fig. 7A). Therefore, we chose to

880 evaluate the potential role of Ubr5 as a target of circRNA-Filip1l. We hypothesized
881 that circRNA-Filip1l facilitates the transcription of Ubr5 through its binding to Ubr5
882 TSS and recruits RNA polymerase. Secondly, to experimentally validate the *in*
883 *silicon* predictions, according to our previous method (Pan et al., 2016), we cloned
884 a 440 bp Ubr5 fragment containing the bound region by circRNA-Filip1l into pGL6
885 reporter vector, and tested the effects of circRNA-Filip1l on the activities of the
886 Ubr5 transcription in HEK293T cells. Expectedly, only pGL6-Ubr5 produced the
887 relative strong luciferase activities compared with the empty vector (Figure 7B),
888 indicating the cloned region contains the regulatory element, and can drive Ubr5
889 expression. The co-transfection of pGL6-Ubr5 with circRNA-Filip1l
890 overexpression plasmid enhanced the luciferase activities by 55.7% compared
891 with co-transfection of pGL6-Ubr5 with empty vector (Fig. 7B). Thirdly, we
892 assessed whether Ubr5 co-express with other regulators, single-cell RT-PCR
893 showed that five of six spinal neurons expressed Ubr5, that four of these five cells
894 co-expressed with circRNA-Filip1l, five of them with miRNA-1224, and four of
895 them with Ago2 (Fig. 7C), suggesting they are able to co-express in the spinal
896 neurons. Thus, we further examined whether circRNA-Filip1l is involved in the
897 regulation of Ubr5 expression *in vivo*. Spinal Ubr5 was significantly increased by
898 67 % day 3 after CFA injection (Fig. 7D, E), suggesting its possible regulatory role
899 in the chronic inflammation pain. Furthermore, the increase of Ubr5 expression
900 was efficiently reversed to the almost basal level day 2 after intrathecal injection of

901 Ubr5-siRNA (Fig. 7D) day 3 after intrathecal injection of PLV-Ubr5 (Lentivirus
902 Ubr5-shRNA) in CFA mice (Fig. 7E). It is apparent from our data that Ubr5-siRNA-
903 or PLV-Ubr5-, but not scramble- or empty vector-injected mice exhibited the
904 anti-nociceptive effects in CFA-induced chronic inflammatory pain model (Fig. 7F,
905 G). These findings indicate the involvement of Ubr5 in the process of chronic pain.

906 Next, we determined whether there is a regulatory role of circRNA-Filip1l in
907 Ubr5 expression *in vivo*. The increase of Ubr5 was abolished by intrathecal
908 injections of anti-Filip1l, but not the scrambled control in CFA mice (Fig. 7H).
909 While, overexpressing circRNA-Filip1l with circRNA-Filip1l mimics (Fig. 7I) or
910 Lenti-Filip1l (Fig. 7J) reduced the level of Ubr5 protein, compared with scrambled
911 or empty vector in naïve mice, suggesting that Ubr5 is a positive regulatory target
912 of circRNA-Filip1l. Finally, to explore the role of Ubr5 in mediating nociceptive
913 regulation by circRNA-Filip1l, we pre- or post- treated animals with Ubr5-siRNA
914 before or after overexpressing spinal circRNA-Filip1l, and then measured the
915 nociceptive responses. Behavioral results showed that the knockdown of Ubr5
916 with intrathecal pre-treatment with PLV-Ubr5 significantly prevented thermal and
917 mechanical nociceptive responses induced by overexpression of circRNA-Filip1l
918 through *i.t.* injection of its mimics (Fig. 7K). Moreover, down-regulation of Ubr5
919 with PLV-Ubr5 post-treatment significantly alleviated thermal and mechanical
920 nociceptive responses induced by Lenti-Filip1l (Fig. 7L). These findings indicate a
921 direct mediatory role of Ubr5 in regulation of nociception by circRNA-Filip1l.

922 Together, these results suggest that spinal circRNA-Filip1l regulates nociception
923 via positively targeting Ubr5. In conclusion, these data indicate that miRNA-1224
924 and Ago2 are involved in the regulation of circRNA-Filip1l-mediated Ubr5
925 expression (Fig. 8).

926

927

928

929

930

931

932

933

934

935

936

937

938

939

940

941

942

943 **Discussion**

944 Chronic pain is one of the most intractable human complaints and is caused by
945 inflammation, lesion or dysfunction of the nervous system (Clark, 2016; Ji et al.,
946 2018; Jing et al., 2018). The expression of aberrant pain-related gene in spinal
947 neuronal or glial cells is the most prominent contributor in various nociceptive
948 pathways underlying chronic pain (Ji et al., 2016; Jiang et al., 2017; Tsuda, 2018).
949 Therefore, the unraveling of the genetic basis and its regulatory mechanisms will
950 improve our insight into chronic pain, and provides potential targets for developing
951 novel therapeutic strategies. Various studies have refined our understanding of
952 miRNAs or long strand ncRNA in the pathway of different pain models, and shown
953 that noncoding RNAs have regulatory functions in the process of nociceptive
954 signal. The current study identified an essential role of circRNA-Filip1l as a
955 mediator of chronic inflammation pain by directly targeting Ubr5 at the spinal level.
956 We further found that miRNA-1224 was an upstream regulator of circRNA-Filip1l
957 in the Ago2-dependent manner. Our results are for the first time to functionally
958 demonstrate that circRNA is an important player to the induction and maintenance
959 of chronic pain.

960 CircRNA, a noncoding RNA as the novel regulatory mechanism of gene
961 expression, attracts widespread attention on their vital roles in biological
962 processes and human diseases. A growing body of evidence suggests that
963 circRNAs are enriched in nervous system, such as different brain regions, primary

964 neurons and isolated synapses (Shao and Chen, 2016), and a number of
965 circRNAs are highly conservation among species, and their expressions are
966 changed during neuronal differentiation (Rybak-Wolf et al., 2015). However, it is
967 only beginning to understand how circRNAs are involved in physiological and
968 pathological processes of nervous system. Several studies have gained an insight
969 into the function of circRNAs in neurological disorders or diseases like
970 Parkinson's disease (Kumar et al., 2018), Alzheimer's disease (Lu and Xu, 2016;
971 Zhao et al., 2016), amyotrophic lateral sclerosis and spinal muscul aratrophy
972 (Scotti and Swanson, 2016). In 2017, circRNA is firstly reported to be associated
973 with brain function --- circRNA-Cdr1as-knockout mice display the impaired
974 sensorimotor gating due to the dysfunction of excitatory synaptic transmission in
975 brain (Piwecka et al., 2017), circRNA serves as a critical player in CNS diseases.
976 Recent work has focused on the relationship between circRNA and pain. Zhou et
977 al (Zhou et al., 2017) and Cao et al (Cao et al., 2017) found that spared nerve
978 injury (SNI)- or chronic constriction injury-induced neuropathic pain causes the
979 expression alteration of 188 or 469 spinal circRNAs, respectively. Despite spinal
980 circRNA profiles are changed in chronic neuropathic pain, it remains unknown
981 whether circRNAs regulate the nociception behavior. The results of this study
982 showed that CFA-induced chronic inflammation pain increased the content of
983 circRNA-Filip1l in spinal cord of mice; knockdown of circRNA-Filip1l alleviated the

984 nociceptive behavior, supporting the idea that circRNA-Filip1l regulates the
985 nociceptive response.

986 MiRNAs are approximately 21 nucleotides in length and well-studied
987 noncoding RNA species in terms of their biogenesis and functions. Increasing
988 evidence over the past few years from different pain models have linked miRNA to
989 nociceptive pathways including membrane receptors (Park et al., 2014; Jiang et
990 al., 2016), ion channels (Pan et al., 2016; Peng et al., 2017), transcription factors
991 (Willemen et al., 2012), translation factors (Sun et al., 2012), and other cellular
992 signals (Zhou et al., 2016), from primary afferent nociceptors, DRG, spinal cord,
993 and brain areas. Previous reports on nucleus miRNAs uncover their importance
994 functions in the RNA splice or transcription (Liao et al., 2010). For example,
995 nucleus miR-671 can mediate the cleavage of circRNA-Cdr1as in mouse brain
996 (Hansen et al., 2011). Although growing number of molecular and functional data
997 support the involvement of cytoplasmic miRNA in the process of chronic pain, little
998 is known about whether nucleus miRNA is related to chronic pain. In our work, the
999 abundant expression of miRNA-1224 was identified in the mouse spinal nucleus.
1000 Indeed, miRNA-1224 has been discovered to differentially express in the liver of
1001 fatty liver disease (Dolganuc et al., 2009), and in different tissues of bladder
1002 cancer (Dudziec et al., 2011), inflammation and acute injured kidney (Niu et al.,
1003 2011; Bellinger et al., 2014; Roy et al., 2017). MiRNA-1224 can be also detected
1004 in hippocampus and the marginal division of the neostriatum in rats (Shu et al.,

1005 [2013](#)). But, Up to now, far too little attention has been paid to the function of
1006 miRNA-1224 in diseases. We provide the first evidence that spinal nucleus
1007 miRNA-1224 is implicated in the modulation of chronic inflammatory pain.
1008 Furthermore, we reveal a novel mechanism of miRNA-122 in the pain process
1009 through splicing circRNA-Filip1l in Ago2-dependent manner.

1010 In fact, it is still challenged to understand how circRNA expression itself is
1011 regulated in pathological processes. Several reports show that antisense
1012 oligonucleotide or miRNA are associated with the splice of circRNA, and change
1013 their expression level ([Havens et al., 2013](#); [Jeck and Sharpless, 2014](#)). As
1014 miRNA-671 almost fully binds to circRNA-Cdr1as to form the miRNA-671-
1015 circRNA-Cdr1as complex in cell nucleus, Ago2 slices circRNA-Cdr1as after
1016 recognizing the complex ([Piwecka et al., 2017](#)). In the present study, we found
1017 that Ago2 recognized and sliced the complex formed by miRNA-1224 and
1018 pre-circRNA-Filip1l, resulting in the reduction of mature circRNA-Filip1l in the
1019 spinal nucleus. Our data suggest that miRNA-mediated Ago2 cleavage for
1020 pre-circRNA may play a crucial role in the modulation of circRNA biogenesis, at
1021 the least, in spinal nucleus. Therefore, combined with previous reports, circRNA
1022 may be regulated through two ways: Ago2 cleaved circRNA or their precursors
1023 after miRNAs binding. Our findings will allow for a new optional strategy in
1024 prevention and treatment of pain or other CNS diseases via affecting circRNA
1025 biogenesis by miRNA.

1026 Ago2, termed as EIF2C2, is a member of Ago family (1, 2, 3 and 4)
1027 characterized with a high conservation among species and broadly expression in
1028 different tissues (Ye et al., 2015). Interestingly, Ago2 is the only one with catalytic
1029 activity among family members, and efficiently silences the expression of small
1030 RNAs. Distinguishing from the other members, mice with Ago2 knockout are
1031 lethal (Shekar et al., 2011). Extensive studies have shown that Ago2 participates
1032 in miRNA generation (Schaefer et al., 2010), miRNA-mediated mRNA degradation
1033 (Meister et al., 2004; Cifuentes et al., 2010), translation repression (Friend et al.,
1034 2012), and hetero-chromatinization (Moshkovich et al., 2011) in Dicer (an
1035 endoribonuclease)-independent means. Knockdown of Ago2 leads to the
1036 decrease of global miRNA (Morita et al., 2007). For example, Ago2, not 1, 3 and 4,
1037 is down-regulated in brain lysates from encephalomyelitis mice, the expression
1038 level of several miRNAs including let-7a-5p, let-7e-5p, let-7f-5p, 106b-5p, 144-3p,
1039 and 188a-5p display a significant reduction (Lewkowicz et al., 2015), suggesting
1040 Ago2 is involved in the etiology of CNS diseases (Savas et al., 2008). Deficiency
1041 of Ago2 in D2R neurons relieves self-administration of cocaine due to the declined
1042 content of miRNAs in the mouse striatum (Schaefer et al., 2010), revealing a vital
1043 role of Ago2 in the treatment of CNS diseases (Carrick et al., 2016). Here, we
1044 found nociceptive behavior caused the decrease of spinal Ago2 level, and
1045 overexpressing Ago2 significantly attenuated the pain hypersensitivity, it can

1046 therefore be concluded that Ago2 is a an important player in nociceptive
1047 response.

1048 Despite a large number of circRNAs have been found, how circRNA regulates
1049 gene expression is a major problem for a long time. The relatively well-studied
1050 mechanism is that circRNA adsorbs miRNAs (a process known as miRNA
1051 sponge), and thereby decreases the binding of miRNAs to their target mRNAs
1052 (Hansen et al., 2013b). As circRNA-HIPK3 adsorbs 9 different miRNAs, the
1053 knockdown of circRNA-HIPK3 inhibits cell growth via enhancing the level of
1054 miRNAs binding to the target mRNAs (Zheng et al., 2016). MiRNA-7 is involved in
1055 the formation of dendritic spine density (Choi et al., 2015; Zhang et al., 2015),
1056 Cdr1as is known as the sponge for miRNA-7 and regulates the stability or
1057 transport of miRNA-7 in neuronal cells, hence, the function-loss-circRNA-Cdr1as
1058 impairs the sensorimotor gating and synaptic transmission of mouse brain tissues
1059 including cerebellum, cortex, hippocampus, and olfactory bulb by enhancing the
1060 number of freely available miRNA-7 (Piwecka et al., 2017). Although, relatively to
1061 act as sponge of miRNAs, only few circRNAs are studied in the function of gene
1062 transcription, it is now well established from various studies that circRNAs can
1063 bind to not only proteins such as AGO and RNA polymerase II (PolII), but also to
1064 linear RNAs and DNAs in cellular nucleus. CircRNA from *Fmn* gene lavishly
1065 presents in nucleus, and promotes the transcription of *Fmn* gene by enhancing
1066 the binding capacity of PolII to *Fmn* promoter (Chao et al., 1998; Zhang et al.,

1067 [2013](#)). Similarly, the complex formed by circRNA-EI and U1 snRNP can also
1068 recruit PolII to the promoter of circRNA-EI parental gene in nucleus, initiating the
1069 transcription process ([Li et al., 2015](#)). Interestingly, circRNA-Mble regulates the
1070 biogenesis of parent linear Mble RNA ([Ashwal-Fluss et al., 2014](#)). Consistently,
1071 our findings showed that circRNA-Filip1l enhanced the transcription level of Ubr5
1072 via binding to the near region in TSS. But, further research should be undertaken
1073 to investigate whether the binding sites recruit the RNA polymerase. Our
1074 observations may provide an approach to obtain the possible downstream targets
1075 of nucleus circRNAs. The findings of the current study support the previous
1076 reports: such lncRNAs as RoX2, TERC, and HOTAIR, are enriched in the
1077 mammalian nucleus, and bind to gene bodies and GA-rich DNA regions to control
1078 gene transcription via recruiting RNA polymerase ([Chu et al., 2011](#); [Bonasio and](#)
1079 [Shiekhattar, 2014](#)). Consequently, we speculate that circRNA or lncRNA may
1080 share the regulatory mechanism of gene expression through transcriptional
1081 interference ([Bonasio and Shiekhattar, 2014](#); [Fatica and Bozzoni, 2014](#)).

1082 Ubr5 is a HECT (homologous to E6-associated protein at the
1083 carboxy-terminus) E3 Ub ligase recognizing n-degrons, and has a catalytic ability
1084 of directly recognizing and ligating ubiquitin to degrading proteins. It is very well
1085 deliberated that Ubr5 participates in CNS-related diseases, such as
1086 neuroinflammation, cognitive disorders and depression ([Gudjonsson et al., 2012](#);
1087 [Rutz et al., 2015](#)). Depression increases Ubr5 expression in the lateral habenula

1088 tissues of rats, the administration of Escitalopram, a selective serotonin reuptake
1089 inhibitor, for 4 weeks alleviates the depression behavior by decreasing the level of
1090 Ubr5 expression (Christensen et al., 2013). Ubr5 mutation clinically impairs the
1091 cognitive capability in Alzheimer disease (Hu et al., 2011), suggesting Ubr5 has
1092 an essential role in CNS diseases. In our work, Ubr5 was significantly increased in
1093 spinal cord of chronic inflammatory pain model, the knockdown of Ubr5
1094 attenuated the pain behavior, and therefore, Ubr5 could serve as an important
1095 regulator in the process chronic pain.

1096 In summary, we demonstrate that spinal miRNA-1224-mediated splice of
1097 circRNA-Filip1l in Ago2-depedent manner regulate chronic inflammatory pain via
1098 targeting Ubr5. These findings shed light on new circRNA mechanism underlying
1099 nociceptive information processing; may provide a rational for the future
1100 development of potential targeted interventions via circRNA modulating
1101 pain-related gene expression.

1102

1103

1104

1105

1106

1107

1108

1109

Reference

- 1110 Ashwal-Fluss R, Meyer M, Pamudurti NR, Ivanov A, Bartok O, Hanan M, Evantal N, Memczak S, Rajewsky N,
1111 Kadener S (2014) circRNA biogenesis competes with pre-mRNA splicing. *Molecular cell* 56:55-66.
- 1112 Bellinger MA, Bean JS, Rader MA, Heinz-Taheny KM, Nunes JS, Haas JV, Michael LF, Reikter MD (2014)
1113 Concordant changes of plasma and kidney microRNA in the early stages of acute kidney injury:
1114 time course in a mouse model of bilateral renal ischemia-reperfusion. *PLoS one* 9:e93297.
- 1115 Bonasio R, Shiekhattar R (2014) Regulation of transcription by long noncoding RNAs. *Annual review of*
1116 *genetics* 48:433-455.
- 1117 Cao S, Deng W, Li Y, Qin B, Zhang L, Yu S, Xie P, Xiao Z, Yu T (2017) Chronic constriction injury of sciatic
1118 nerve changes circular RNA expression in rat spinal dorsal horn. *Journal of pain research*
1119 10:1687-1696.
- 1120 Carrick WT, Burks B, Cairns MJ, Kocerha J (2016) Noncoding RNA Regulation of Dopamine Signaling in
1121 Diseases of the Central Nervous System. *Frontiers in molecular biosciences* 3:69.
- 1122 Chao CW, Chan DC, Kuo A, Leder P (1998) The mouse formin (Fmn) gene: abundant circular RNA
1123 transcripts and gene-targeted deletion analysis. *Molecular medicine* 4:614-628.
- 1124 Chen W, Schuman E (2016) Circular RNAs in Brain and Other Tissues: A Functional Enigma. *Trends in*
1125 *neurosciences* 39:597-604.
- 1126 Choi SY, Pang K, Kim JY, Ryu JR, Kang H, Liu Z, Kim WK, Sun W, Kim H, Han K (2015) Post-transcriptional
1127 regulation of SHANK3 expression by microRNAs related to multiple neuropsychiatric disorders.
1128 *Molecular brain* 8:74.
- 1129 Christensen T, Jensen L, Bouzinova EV, Wiborg O (2013) Molecular profiling of the lateral habenula in a rat
1130 model of depression. *PLoS one* 8:e80666.
- 1131 Chu C, Qu K, Zhong FL, Artandi SE, Chang HY (2011) Genomic maps of long noncoding RNA occupancy
1132 reveal principles of RNA-chromatin interactions. *Molecular cell* 44:667-678.
- 1133 Cifuentes D, Xue H, Taylor DW, Patnode H, Mishima Y, Cheloufi S, Ma E, Mane S, Hannon GJ, Lawson ND,
1134 Wolfe SA, Giraldez AJ (2010) A novel miRNA processing pathway independent of Dicer requires
1135 Argonaute2 catalytic activity. *Science* 328:1694-1698.
- 1136 Clark JD (2016) Preclinical Pain Research: Can We Do Better? *Anesthesiology* 125:846-849.
- 1137 Descalzi G, Ikegami D, Ushijima T, Nestler EJ, Zachariou V, Narita M (2015) Epigenetic mechanisms of
1138 chronic pain. *Trends in neurosciences* 38:237-246.
- 1139 Dolganiuc A, Petrasek J, Kodys K, Catalano D, Mandrekar P, Velayudham A, Szabo G (2009) MicroRNA
1140 expression profile in Lieber-DeCarli diet-induced alcoholic and methionine choline deficient
1141 diet-induced nonalcoholic steatohepatitis models in mice. *Alcoholism, clinical and experimental*
1142 *research* 33:1704-1710.
- 1143 Dudzic E, Miah S, Choudhry HM, Owen HC, Blizard S, Glover M, Hamdy FC, Catto JW (2011)
1144 Hypermethylation of CpG islands and shores around specific microRNAs and mirtrons is
1145 associated with the phenotype and presence of bladder cancer. *Clinical cancer research : an*
1146 *official journal of the American Association for Cancer Research* 17:1287-1296.
- 1147 Fatica A, Bozzoni I (2014) Long non-coding RNAs: new players in cell differentiation and development.
1148 *Nature reviews Genetics* 15:7-21.

- 1149 Friend K, Campbell ZT, Cooke A, Kroll-Conner P, Wickens MP, Kimble J (2012) A conserved PUF-Ago-eEF1A
1150 complex attenuates translation elongation. *Nature structural & molecular biology* 19:176-183.
- 1151 Gandla J, Lomada SK, Lu J, Kuner R, Bali KK (2017) miR-34c-5p functions as pronociceptive microRNA in
1152 cancer pain by targeting Cav2.3 containing calcium channels. *Pain*.
- 1153 Glazar P, Papavasileiou P, Rajewsky N (2014) circBase: a database for circular RNAs. *Rna* 20:1666-1670.
- 1154 Gudjonsson T, Altmeyer M, Savic V, Toledo L, Dinant C, Grofte M, Bartkova J, Poulsen M, Oka Y,
1155 Bekker-Jensen S, Mailand N, Neumann B, Heriche JK, Shearer R, Saunders D, Bartek J, Lukas J,
1156 Lukas C (2012) TRIP12 and UBR5 suppress spreading of chromatin ubiquitylation at damaged
1157 chromosomes. *Cell* 150:697-709.
- 1158 Hansen TB, Kjems J, Damgaard CK (2013a) Circular RNA and miR-7 in cancer. *Cancer research*
1159 73:5609-5612.
- 1160 Hansen TB, Wiklund ED, Bramsen JB, Villadsen SB, Statham AL, Clark SJ, Kjems J (2011) miRNA-dependent
1161 gene silencing involving Ago2-mediated cleavage of a circular antisense RNA. *The EMBO journal*
1162 30:4414-4422.
- 1163 Hansen TB, Jensen TI, Clausen BH, Bramsen JB, Finsen B, Damgaard CK, Kjems J (2013b) Natural RNA
1164 circles function as efficient microRNA sponges. *Nature* 495:384-388.
- 1165 Havens MA, Duelli DM, Hastings ML (2013) Targeting RNA splicing for disease therapy. *Wiley*
1166 *interdisciplinary reviews RNA* 4:247-266.
- 1167 Holdt LM, Stahringer A, Sass K, Pichler G, Kulak NA, Wilfert W, Kohlmaier A, Herbst A, Northoff BH,
1168 Nicolaou A, Gabel G, Beutner F, Scholz M, Thiery J, Musunuru K, Krohn K, Mann M, Teupser D
1169 (2016) Circular non-coding RNA ANRIL modulates ribosomal RNA maturation and atherosclerosis
1170 in humans. *Nature communications* 7:12429.
- 1171 Hu X, Pickering EH, Hall SK, Naik S, Liu YC, Soares H, Katz E, Paciga SA, Liu W, Aisen PS, Bales KR, Samad TA,
1172 John SL (2011) Genome-wide association study identifies multiple novel loci associated with
1173 disease progression in subjects with mild cognitive impairment. *Translational psychiatry* 1:e54.
- 1174 Hugel S, Schlichter R (2000) Presynaptic P2X receptors facilitate inhibitory GABAergic transmission
1175 between cultured rat spinal cord dorsal horn neurons. *The Journal of neuroscience : the official*
1176 *journal of the Society for Neuroscience* 20:2121-2130.
- 1177 Hunsberger JG, Fessler EB, Wang Z, Elkahlon AG, Chuang DM (2012) Post-insult valproic acid-regulated
1178 microRNAs: potential targets for cerebral ischemia. *American journal of translational research*
1179 4:316-332.
- 1180 Imai S et al. (2013) Epigenetic transcriptional activation of monocyte chemotactic protein 3 contributes to
1181 long-lasting neuropathic pain. *Brain : a journal of neurology* 136:828-843.
- 1182 Jeck WR, Sharpless NE (2014) Detecting and characterizing circular RNAs. *Nature biotechnology*
1183 32:453-461.
- 1184 Ji RR, Chamessian A, Zhang YQ (2016) Pain regulation by non-neuronal cells and inflammation. *Science*
1185 354:572-577.
- 1186 Ji RR, Nackley A, Huh Y, Terrando N, Maixner W (2018) Neuroinflammation and Central Sensitization in
1187 Chronic and Widespread Pain. *Anesthesiology*.
- 1188 Jiang BC, He LN, Wu XB, Shi H, Zhang WW, Zhang ZJ, Cao DL, Li CH, Gu J, Gao YJ (2017) Promoted
1189 Interaction of C/EBPalpha with Demethylated Cxcr3 Gene Promoter Contributes to Neuropathic

- 1190 Pain in Mice. *The Journal of neuroscience : the official journal of the Society for Neuroscience*
 1191 37:685-700.
- 1192 Jiang BC, Cao DL, Zhang X, Zhang ZJ, He LN, Li CH, Zhang WW, Wu XB, Berta T, Ji RR, Gao YJ (2016) CXCL13
 1193 drives spinal astrocyte activation and neuropathic pain via CXCR5. *The Journal of clinical*
 1194 *investigation* 126:745-761.
- 1195 Jing PB, Cao DL, Li SS, Zhu M, Bai XQ, Wu XB, Gao YJ (2018) Chemokine Receptor CXCR3 in the Spinal Cord
 1196 Contributes to Chronic Itch in Mice. *Neuroscience bulletin* 34:54-63.
- 1197 Kato T, Tamiya G, Koyama S, Nakamura T, Makino S, Arawaka S, Kawanami T, Tooyama I (2012) UBR5 Gene
 1198 Mutation Is Associated with Familial Adult Myoclonic Epilepsy in a Japanese Family. *ISRN*
 1199 *neurology* 2012:508308.
- 1200 Kumar L, Shamsuzzama, Jadiya P, Haque R, Shukla S, Nazir A (2018) Functional Characterization of Novel
 1201 Circular RNA Molecule, circzip-2 and Its Synthesizing Gene zip-2 in *C. elegans* Model of
 1202 Parkinson's Disease. *Molecular neurobiology*.
- 1203 Legnini I, Di Timoteo G, Rossi F, Morlando M, Briganti F, Sthandier O, Fatica A, Santini T, Andronache A,
 1204 Wade M, Laneve P, Rajewsky N, Bozzoni I (2017) Circ-ZNF609 Is a Circular RNA that Can Be
 1205 Translated and Functions in Myogenesis. *Molecular cell* 66:22-37 e29.
- 1206 Lewkowicz P, Cwiklinska H, Mycko MP, Cichalewska M, Domowicz M, Lewkowicz N, Jurewicz A, Selmaj KW
 1207 (2015) Dysregulated RNA-Induced Silencing Complex (RISC) Assembly within CNS Corresponds
 1208 with Abnormal miRNA Expression during Autoimmune Demyelination. *The Journal of*
 1209 *neuroscience : the official journal of the Society for Neuroscience* 35:7521-7537.
- 1210 Li Z, Huang C, Bao C, Chen L, Lin M, Wang X, Zhong G, Yu B, Hu W, Dai L, Zhu P, Chang Z, Wu Q, Zhao Y, Jia Y,
 1211 Xu P, Liu H, Shan G (2015) Exon-intron circular RNAs regulate transcription in the nucleus. *Nature*
 1212 *structural & molecular biology* 22:256-264.
- 1213 Liao JY, Ma LM, Guo YH, Zhang YC, Zhou H, Shao P, Chen YQ, Qu LH (2010) Deep sequencing of human
 1214 nuclear and cytoplasmic small RNAs reveals an unexpectedly complex subcellular distribution of
 1215 miRNAs and tRNA 3' trailers. *PloS one* 5:e10563.
- 1216 Long Y, Wang X, Youmans DT, Cech TR (2017) How do lncRNAs regulate transcription? *Science advances*
 1217 3:eaa02110.
- 1218 Lu D, Xu AD (2016) Mini Review: Circular RNAs as Potential Clinical Biomarkers for Disorders in the Central
 1219 Nervous System. *Frontiers in genetics* 7:53.
- 1220 Meister G, Landthaler M, Patkaniowska A, Dorsett Y, Teng G, Tuschl T (2004) Human Argonaute2 mediates
 1221 RNA cleavage targeted by miRNAs and siRNAs. *Molecular cell* 15:185-197.
- 1222 Memczak S, Jens M, Elefsinioti A, Torti F, Krueger J, Rybak A, Maier L, Mackowiak SD, Gregersen LH,
 1223 Munschauer M, Loewer A, Ziebold U, Landthaler M, Kocks C, Ie Noble F, Rajewsky N (2013)
 1224 Circular RNAs are a large class of animal RNAs with regulatory potency. *Nature* 495:333-338.
- 1225 Monif M, Reid CA, Powell KL, Drummond KJ, O'Brien TJ, Williams DA (2016) Interleukin-1beta has trophic
 1226 effects in microglia and its release is mediated by P2X7R pore. *Journal of neuroinflammation*
 1227 13:173.
- 1228 Morita S, Horii T, Kimura M, Goto Y, Ochiya T, Hatada I (2007) One Argonaute family member, Eif2c2
 1229 (Ago2), is essential for development and appears not to be involved in DNA methylation.
 1230 *Genomics* 89:687-696.

- 1231 Moshkovich N, Nisha P, Boyle PJ, Thompson BA, Dale RK, Lei EP (2011) RNAi-independent role for
1232 Argonaute2 in CTCF/CP190 chromatin insulator function. *Genes & development* 25:1686-1701.
- 1233 Niu Y, Mo D, Qin L, Wang C, Li A, Zhao X, Wang X, Xiao S, Wang Q, Xie Y, He Z, Cong P, Chen Y (2011)
1234 Lipopolysaccharide-induced miR-1224 negatively regulates tumour necrosis factor-alpha gene
1235 expression by modulating Sp1. *Immunology* 133:8-20.
- 1236 Pan Z, Xue ZY, Li GF, Sun ML, Zhang M, Hao LY, Tang QQ, Zhu LJ, Cao JL (2017) DNA Hydroxymethylation by
1237 Ten-eleven Translocation Methylcytosine Dioxygenase 1 and 3 Regulates Nociceptive Sensitization
1238 in a Chronic Inflammatory Pain Model. *Anesthesiology* 127:147-163.
- 1239 Pan Z, Zhang M, Ma T, Xue ZY, Li GF, Hao LY, Zhu LJ, Li YQ, Ding HL, Cao JL (2016) Hydroxymethylation of
1240 microRNA-365-3p Regulates Nociceptive Behaviors via Kcnn2. *The Journal of neuroscience : the
1241 official journal of the Society for Neuroscience* 36:2769-2781.
- 1242 Pan Z, Zhu LJ, Li YQ, Hao LY, Yin C, Yang JX, Guo Y, Zhang S, Hua L, Xue ZY, Zhang H, Cao JL (2014) Epigenetic
1243 modification of spinal miR-219 expression regulates chronic inflammation pain by targeting
1244 CaMKIIgamma. *The Journal of neuroscience : the official journal of the Society for Neuroscience*
1245 34:9476-9483.
- 1246 Park CK, Xu ZZ, Berta T, Han Q, Chen G, Liu XJ, Ji RR (2014) Extracellular microRNAs activate nociceptor
1247 neurons to elicit pain via TLR7 and TRPA1. *Neuron* 82:47-54.
- 1248 Peng C, Li L, Zhang MD, Bengtsson Gonzales C, Parisien M, Belfer I, Usoskin D, Abdo H, Furlan A, Haring M,
1249 Lallemand F, Harkany T, Diatchenko L, Hokfelt T, Hjerling-Leffler J, Ernfors P (2017) miR-183 cluster
1250 scales mechanical pain sensitivity by regulating basal and neuropathic pain genes. *Science*
1251 356:1168-1171.
- 1252 Piwecka M, Glazar P, Hernandez-Miranda LR, Memczak S, Wolf SA, Rybak-Wolf A, Filipchuk A, Klironomos F,
1253 Cerda Jara CA, Fenske P, Trimbuch T, Zywitza V, Plass M, Schreyer L, Ayoub S, Kocks C, Kuhn R,
1254 Rosenmund C, Birchmeier C, Rajewsky N (2017) Loss of a mammalian circular RNA locus causes
1255 miRNA deregulation and affects brain function. *Science* 357.
- 1256 Rasko JE, Wong JJ (2017) Nuclear microRNAs in normal hemopoiesis and cancer. *Journal of hematology &
1257 oncology* 10:8.
- 1258 Roberts TC (2014) The MicroRNA Biology of the Mammalian Nucleus. *Molecular therapy Nucleic acids*
1259 3:e188.
- 1260 Roy S, Bantel H, Wandrer F, Theres Schneider A, Gautheron J, Vucur M, Tacke F, Trautwein C, Luedde T,
1261 Roderburg C (2017) miR-1224 inhibits cell proliferation in acute liver failure by targeting the
1262 antiapoptotic gene Nfib. *Journal of hepatology*.
- 1263 Rutz S et al. (2015) Deubiquitinase DUBA is a post-translational brake on interleukin-17 production in T
1264 cells. *Nature* 518:417-421.
- 1265 Rybak-Wolf A, Stottmeister C, Glazar P, Jens M, Pino N, Giusti S, Hanan M, Behm M, Bartok O, Ashwal-Fluss
1266 R, Herzog M, Schreyer L, Papavasileiou P, Ivanov A, Ohman M, Refojo D, Kadener S, Rajewsky N
1267 (2015) Circular RNAs in the Mammalian Brain Are Highly Abundant, Conserved, and Dynamically
1268 Expressed. *Molecular cell* 58:870-885.
- 1269 Savas JN, Makusky A, Ottosen S, Baillat D, Then F, Krainc D, Shiekhhattar R, Markey SP, Tanese N (2008)
1270 Huntington's disease protein contributes to RNA-mediated gene silencing through association

- 1271 with Argonaute and P bodies. Proceedings of the National Academy of Sciences of the United
1272 States of America 105:10820-10825.
- 1273 Schaefer A, Im HI, Veno MT, Fowler CD, Min A, Intrator A, Kjemis J, Kenny PJ, O'Carroll D, Greengard P
1274 (2010) Argonaute 2 in dopamine 2 receptor-expressing neurons regulates cocaine addiction. The
1275 Journal of experimental medicine 207:1843-1851.
- 1276 Scotti MM, Swanson MS (2016) RNA mis-splicing in disease. Nature reviews Genetics 17:19-32.
- 1277 Shao Y, Chen Y (2016) Roles of Circular RNAs in Neurologic Disease. Frontiers in molecular neuroscience
1278 9:25.
- 1279 Shekar PC, Naim A, Sarathi DP, Kumar S (2011) Argonaute-2-null embryonic stem cells are retarded in
1280 self-renewal and differentiation. Journal of biosciences 36:649-657.
- 1281 Shu SY, Qing D, Wang B, Zeng QY, Chen YC, Jin Y, Zeng CC, Bao R (2013) Comparison of microRNA
1282 expression in hippocampus and the marginal division (MrD) of the neostriatum in rats. Journal of
1283 biomedical science 20:9.
- 1284 Sibley CR, Seow Y, Curtis H, Weinberg MS, Wood MJ (2012) Silencing of Parkinson's disease-associated
1285 genes with artificial mirtron mimics of miR-1224. Nucleic acids research 40:9863-9875.
- 1286 Su X, Wang H, Ge W, Yang M, Hou J, Chen T, Li N, Cao X (2015) An In Vivo Method to Identify microRNA
1287 Targets Not Predicted by Computation Algorithms: p21 Targeting by miR-92a in Cancer. Cancer
1288 research 75:2875-2885.
- 1289 Sun Y, Li XQ, Sahbaie P, Shi XY, Li WW, Liang DY, Clark JD (2012) miR-203 regulates nociceptive sensitization
1290 after incision by controlling phospholipase A2 activating protein expression. Anesthesiology
1291 117:626-638.
- 1292 Tao YX, Rumbaugh G, Wang GD, Petralia RS, Zhao C, Kauer FW, Tao F, Zhuo M, Wenthold RJ, Raja SN,
1293 Haganir RL, Bredt DS, Johns RA (2003) Impaired NMDA receptor-mediated postsynaptic function
1294 and blunted NMDA receptor-dependent persistent pain in mice lacking postsynaptic density-93
1295 protein. The Journal of neuroscience : the official journal of the Society for Neuroscience
1296 23:6703-6712.
- 1297 Tsuda M (2018) Modulation of Pain and Itch by Spinal Glia. Neuroscience bulletin 34:178-185.
- 1298 Willemsen HL, Huo XJ, Mao-Ying QL, Zijlstra J, Heijnen CJ, Kavelaars A (2012) MicroRNA-124 as a novel
1299 treatment for persistent hyperalgesia. Journal of neuroinflammation 9:143.
- 1300 Yang JX, Hua L, Li YQ, Jiang YY, Han D, Liu H, Tang QQ, Yang XN, Yin C, Hao LY, Yu L, Wu P, Shao CJ, Ding HL,
1301 Zhang YM, Cao JL (2015) Caveolin-1 in the anterior cingulate cortex modulates chronic
1302 neuropathic pain via regulation of NMDA receptor 2B subunit. The Journal of neuroscience : the
1303 official journal of the Society for Neuroscience 35:36-52.
- 1304 Ye Z, Jin H, Qian Q (2015) Argonaute 2: A Novel Rising Star in Cancer Research. Journal of Cancer
1305 6:877-882.
- 1306 You X, Vlatkovic I, Babic A, Will T, Epstein I, Tushev G, Akbalik G, Wang M, Glock C, Quedenau C, Wang X,
1307 Hou J, Liu H, Sun W, Sambandan S, Chen T, Schuman EM, Chen W (2015) Neural circular RNAs are
1308 derived from synaptic genes and regulated by development and plasticity. Nature neuroscience
1309 18:603-610.
- 1310 Zhang J, Sun XY, Zhang LY (2015) MicroRNA-7/Shank3 axis involved in schizophrenia pathogenesis. Journal
1311 of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 22:1254-1257.

- 1312 Zhang L, Chung SK, Chow BK (2014) The knockout of secretin in cerebellar Purkinje cells impairs mouse
1313 motor coordination and motor learning. *Neuropsychopharmacology* : official publication of the
1314 American College of Neuropsychopharmacology 39:1460-1468.
- 1315 Zhang S, Yang XN, Zang T, Luo J, Pan Z, Wang L, Liu H, Liu D, Li YQ, Zhang YD, Zhang H, Ding HL, Cao JL
1316 (2017) Astroglial MicroRNA-219-5p in the Ventral Tegmental Area Regulates Nociception in Rats.
1317 *Anesthesiology* 127:548-564.
- 1318 Zhang Y, Zhang XO, Chen T, Xiang JF, Yin QF, Xing YH, Zhu S, Yang L, Chen LL (2013) Circular intronic long
1319 noncoding RNAs. *Molecular cell* 51:792-806.
- 1320 Zhao X, Tang Z, Zhang H, Atianjoh FE, Zhao JY, Liang L, Wang W, Guan X, Kao SC, Tiwari V, Gao YJ, Hoffman
1321 PN, Cui H, Li M, Dong X, Tao YX (2013) A long noncoding RNA contributes to neuropathic pain by
1322 silencing Kcna2 in primary afferent neurons. *Nature neuroscience* 16:1024-1031.
- 1323 Zhao Y, Alexandrov PN, Jaber V, Lukiw WJ (2016) Deficiency in the Ubiquitin Conjugating Enzyme UBE2A in
1324 Alzheimer's Disease (AD) is Linked to Deficits in a Natural Circular miRNA-7 Sponge (circRNA;
1325 ciRS-7). *Genes* 7.
- 1326 Zheng Q, Bao C, Guo W, Li S, Chen J, Chen B, Luo Y, Lyu D, Li Y, Shi G, Liang L, Gu J, He X, Huang S (2016)
1327 Circular RNA profiling reveals an abundant circHIPK3 that regulates cell growth by sponging
1328 multiple miRNAs. *Nature communications* 7:11215.
- 1329 Zhou J, Xiong Q, Chen H, Yang C, Fan Y (2017) Identification of the Spinal Expression Profile of Non-coding
1330 RNAs Involved in Neuropathic Pain Following Spared Nerve Injury by Sequence Analysis. *Frontiers*
1331 *in molecular neuroscience* 10:91.
- 1332 Zhou Q, Yang L, Larson S, Basra S, Merwat S, Tan A, Croce C, Verne GN (2016) Decreased miR-199
1333 augments visceral pain in patients with IBS through translational upregulation of TRPV1. *Gut*
1334 65:797-805.
- 1335
- 1336
- 1337
- 1338
- 1339
- 1340
- 1341
- 1342
- 1343

1344 **Figure legends**

1345

1346 **Figure 1.** Profiling of circRNAs and circRNA-Filip1l expression in mouse spinal
1347 cord. **A,** The expression profiling of differential circRNAs with 2 fold or more was
1348 generated from circRNA microarray. Spinal cord was collected 3 day after CFA- or
1349 Saline-injection. $n = 3$ per group. The number presents the identification of
1350 circRNA in Arraystar Mouse circRNA's Microarray. **B,** Four differential circRNAs
1351 were subjected to qRT-PCR verification. $n = 4$ per group; no significance versus
1352 the corresponding microarray groups by two-tailed paired Student's t test. **C,** The
1353 genomic loci of circRNA-Filip1l (ciR-Filip1l) is shown. The junction of
1354 circRNA-Filip1l was amplified by the use of back-to-back primers, and then
1355 sequenced by Sanger-Sequencing. Arrows represent divergent primers binding to
1356 the genome region of circRNA-Filip1l. **D,** Total RNAs were digested with RNase R
1357 followed by qRT-PCR detection of circRNA-Filip1l expression. Filip1l mRNA was
1358 detected as the RNase R-sensitive control. $n = 4$ per group; *** $p < 0.001$ versus the
1359 corresponding mock groups by two-tailed paired Student's t test. **E,** Northern blot
1360 for circRNA-Filip1l in spinal cord of mice. SC, spinal cord; M, RNA marker. **F,**
1361 Distribution of circRNA-Filip1l in the nucleus and cytoplasm of spinal neuron
1362 cultured *in vitro*. Gapdh represents coding RNA control; Malat1, noncoding RNA
1363 control. Their levels were normalized to Gapdh. Spinal nucleus and cytoplasm
1364 RNA were collected respectively from 48 h cultured mouse spinal neurons *in vitro*.

1365 $n = 4$ per group. **G**, CircRNA-Filip1l FISH in the spinal neuron cultured *in vitro*.

1366 DAPI, nucleus staining dyes.

1367

1368 **Figure 2.** Chronic inflammatory pain induces the increase of spinal
1369 circRNA-Filip1l. **A, B**, Chronic inflammatory pain time-dependently led to the
1370 increase of circRNA-Filip1l in the ipsilateral (Ipsil) spinal dorsal horn (A), and to
1371 the slight increase of Ipsil spinal ventral horn (B) of mice. $n = 5$ per group; * $p < 0.05$,
1372 ** $p < 0.01$ versus the corresponding Sal groups by two-tailed paired Student's t test.

1373 **C, D**, The injection of CFA did not change the expression of circRNA-Filip1l in the
1374 contralateral (Contral) spinal dorsal horn (C), and the Ipsil DRG (D) of mice. $n = 5$
1375 per group; no significance, versus the corresponding Sal groups by two-tailed
1376 paired Student's t test. **E, F**, Neuropathic pain induced by chronic constriction
1377 injury altered the content of circRNA-Filip1l day 3, 7 and 14 in spinal cord (C), but
1378 not in DRG (D) after surgery. $n = 5$ per group; * $p < 0.05$ versus the related Sham
1379 groups by two-tailed paired Student's t test. **G**, Combined circRNA-Filip1l FISH
1380 (green) and NeuN (a neuronal marker, red) immunofluorescence staining in spinal
1381 cord day 3 after CFA or saline injections. Scale bar, 25 μm . **H**, The relative level of
1382 circRNA-Filip1l was analyzed by RT-PCR, respectively in spinal neurons, and
1383 astrocytes and microglial cells cultured *in vitro*. $n = 6$ per group; *** $p < 0.001$ versus
1384 the related microglial groups by two-tailed paired Student's t test. **I**,
1385 circRNA-Filip1l was increased after treatment with KCl (50mM) for 12 h in cultured

1386 spinal neurons. $n = 6$ per group; $**p < 0.01$ versus the related naïve groups by
1387 two-tailed paired Student's t test. **J**, Single cell real-time polymerase chain
1388 reaction (RT-PCR) shows the co-localization of circRNA-Filip1l with NeuN. Nos.
1389 1–6 represents six different neurons; No. 7 (N) is a negative control. The spinal
1390 neurons were isolated from day 2 after CFA-injected mice with 4 weeks-old.

1391

1392 **Figure 3.** CircRNA-Filip1l contributes to nociceptive behavior. **A**, The infection of
1393 PLV-anti-Filip1l with GFP reporter in spinal cord of naïve mice day 3 after 2
1394 consecutive days' intrathecal injection (day 5 after the first injection). NeuN, a
1395 neuron marker. Scale bar, 25 μm . **B, C**, Inhibition of circRNA-Filip1l alleviated the
1396 thermal hyperalgesia and mechanical allodynia after 2 consecutive days'
1397 intrathecal injections of anti-Filip1l (**B**) or PLV-anti-Filip1l (**C**) in CFA mice. $n = 6$
1398 per group; $*p < 0.05$, $**p < 0.01$; two-way ANOVA (effect vs. group \times time interaction)
1399 followed by post hoc Tukey test. Red arrow indicates CFA or saline injections;
1400 blue arrow, anti-Filip1l or Scr and PLV-anti-Filip1l or Vector injections. The
1401 anti-Filip1l sequence was antisense strand of full length of circRNA beginning
1402 from junction. **D, E**, Intrathecal injections of circRNA-Filip1l mimics (**D**) or
1403 Lenti-Filip1l (**E**) for 2 consecutive days increased the spinal circRNA-Filip1l
1404 content in naïve mice. $n = 5$ per group; $p < 0.05$, or $**p < 0.01$; two-tailed paired
1405 Student's t test. **F**, The infection of Lenti-Filip1l with GFP reporter in spinal cord of
1406 naïve mice day 3 after 2 consecutive days' intrathecal injection. Scale bar, 25 μm .

1407 **G, H**, Overexpression of circRNA-Filip1I induced the generation of pain-like
1408 behavior after 2 consecutive days' intrathecal injections of circRNA-Filip1I mimics
1409 (**G**) or Lenti-Filip1I (**H**). $n = 6$ per group; * $p < 0.05$, ** $p < 0.01$; two-way ANOVA
1410 (effect vs. group \times time interaction) followed by post hoc Tukey test. Blue arrow,
1411 circRNA-Filip1I mimics or Scr and Lenti-Filip1I or Lenti-vector injections.

1412

1413 **Figure 4.** MiRNA-1224 is an upstream negative regulator of circRNA-Filip1I. **A**,
1414 Schematic presentation of miRNA-1224 (miR-1224) binding to the fragment of
1415 pre-circRNA-Filip1I (pre-ciR-Filip1I). Underlined presents circRNA-Filip1I; blue,
1416 the reverse complementary of miR-1224 to pre-ciR-Filip1I. **B**, Distribution of
1417 miRNA-1224 in the nucleus and cytoplasm of spinal neuron cultured *in vitro*. $n =$
1418 4 per group. Spinal nucleus and cytoplasm RNA were separated from spinal
1419 neurons cultured *in vitro* for 48 h. **C**, miRNA-1224 FISH in the spinal neuron
1420 cultured *in vitro*. **D**, CFA induced the time-dependent decrease of spinal
1421 miRNA-1224. $n = 5$ per group; * $p < 0.05$, ** $p < 0.01$ versus the corresponding Sal
1422 groups by two-tailed paired Student's *t* test. **E**, Combining FISH of miRNA-1224
1423 and IF of NeuN. Scale bar, 25 μm . **F**, The validation of miR-1224 negatively
1424 regulating circRNA-Filip1I by luciferase report assay *in vitro*. A fragment of
1425 pre-circRNA-Filip1I containing the bound region by miRNA-1224 was inserted into
1426 psiCHECK reporter vectors (psiCK-wt-pre-Filip1I). A mutation was generated via
1427 altering the sequence bound by miRNA-1224 as indicated (psiCK-mut-pre-Filip1I).

1428 The wild and mutation reporters were co-transfected into the HEK293T with
1429 miRNA-1224 mimics or inhibitor or the scrambled. $n = 4$ per group; $*p < 0.05$;
1430 two-way ANOVA (effect vs. plasmid \times treated interaction) followed by post hoc
1431 Tukey test. **G**, Test for the binding capacity of miRNA-1224 to pre-circRNA-Filip1l
1432 *in vivo*. Spinal cord was harvested hour 24 after intrathecal injection of
1433 Bio-miRNA-1224 probes, fixed by formaldehyde, and the bound
1434 pre-circRNA-Filip1l was pull down by Dynabeads M-280 Streptavidin. $n = 4$ per
1435 group; $*p < 0.05$ versus Sal group by two-tailed paired Student's t test. **H**, *In vitro*
1436 transfection of miRNA-1224 mimics or Lenti-1224 enhanced the miRNA-1224
1437 level in HEK293T hour 48 after treatment. $n = 4$ per group; $**p < 0.01$ versus the
1438 corresponding groups by two-tailed paired Student's t test. **I**, Intrathecal injections
1439 of miRNA-1224 mimics or Lenti-1224 for 2 consecutive days increased the
1440 miRNA-1224 content in spinal cord of naïve mice. $n = 4$ per group; $p^* < 0.05$,
1441 $**p < 0.01$; one-way ANOVA (expression vs. the treated groups) followed by post
1442 hoc Tukey test. **J**, **K**, Intrathecal injections of miRNA-1224 mimics (**J**) or
1443 Lenti-1224 (**K**) for 2 consecutive days inhibited the expression of spinal
1444 circRNA-Filip1l, not changed the spinal pre-circRNA-Filip1l level day 2 after last
1445 injection in CFA mice. $n = 5$ per group; $**p < 0.01$; one-way ANOVA (expression vs.
1446 the treated groups) followed by post hoc Tukey test. **L**, **M**, Intrathecal injections of
1447 miRNA-1224 inhibitor (**L**) or PLV-1224-sponge (**M**) for 2 consecutive days
1448 increased the expression of spinal circRNA-Filip1l, not changed the spinal

1449 pre-circRNA-Filip1l level day 3 after last injection in naïve mice. $n = 5$ per group;
1450 $**p < 0.01$ versus the corresponding control groups by two-tailed paired Student's t
1451 test.

1452

1453 **Figure 5.** MiRNA-1224 modulates the nociceptive behavior through the mediation
1454 of circRNA-Filip1l. **A, B,** Intrathecal injections of miRNA-1224 mimics (**A**) or
1455 Lenti-1224 (**B**) for 2 consecutive days reversed CFA-induced thermal
1456 hyperalgesia and mechanical allodynia during the maintenance period. $n = 6$ per
1457 group; $*p < 0.05$, $**p < 0.01$; two-way ANOVA (effect vs. group \times time interaction)
1458 followed by post hoc Tukey test. Red arrow indicates CFA or Sal injections; blue
1459 arrow miRNA-1224 mimics or Scr and Lenti-1224 or Lenti-vector injections. **C,**
1460 Intrathecal pre-injection of Lenti-1224 for 2 consecutive days prevented the
1461 CFA-induced pain hypersensitivity during the development period. $n = 6$ per group;
1462 $*p < 0.05$, $**p < 0.01$; two-way ANOVA (effect vs. group \times time interaction) followed
1463 by post hoc Tukey test. Blue arrow, Lenti-1224 or Lenti-vector injections; red
1464 arrow, CFA or Sal injections. **D, E,** Intrathecal injections of miRNA-1224 inhibitor
1465 (**D**) or PLV-1224 (**E**) for 2 consecutive days produced pain-like behavior in naïve
1466 mice. $n = 6$ per group; $*p < 0.05$, $**p < 0.01$; two-way ANOVA (effect vs. group \times time
1467 interaction) followed by post hoc Tukey test. Black arrow, miRNA-1224 inhibitor or
1468 Scr and PLV-1224 or Vector injections. **F,** Intrathecal injection of anti-Filip1l
1469 significantly inhibited or prevented the pain hypersensitivity induced by PLV-1224

1470 in naïve mice. $n = 6$ per group; $*p < 0.05$; two-way ANOVA (effect vs. group \times time
1471 interaction) followed by post hoc Tukey test. Red arrow, PLV-1224 injection; blue
1472 arrow, anti-Filip1l or Scr injection. **G**, Pre-treatment with anti-Filip1l significantly
1473 inhibited the pain hypersensitivity induced by miRNA-1224 inhibitor in naïve mice.
1474 $n = 6$ per group; $*p < 0.05$; two-way ANOVA (effect vs. group \times time interaction)
1475 followed by post hoc Tukey test. Red arrow, miRNA-1224 inhibitor injection; blue
1476 arrow, anti-Filip1l or Scr injections.

1477

1478 **Figure 6.** Ago2 mediates circRNA-Filip1l expression by cleavage of the
1479 pre-circRNA-Filip1l, and regulates the nociceptive behavior. **A**, Luciferase
1480 activities of reporter plasmid after co-transfection of miRNA-1224 mimics, Ago2
1481 overexpression plasmid (Lenti-Ago2) or empty vector (Lenti-vector), and
1482 psiCK-mut-pre-Filip1l or psiCK-wt-pre-Filip1l into HEK293T. $n = 4$ per group;
1483 $*p < 0.05$, $**p < 0.01$; two-way ANOVA (effect vs. plasmid \times treated interaction)
1484 followed by post hoc Tukey test. **B**, Co-immunoprecipitation of Ago2 and
1485 pre-circRNA-Filip1l or miRNA-1224. The pre-circRNA-Filip1l, miRNA-1224 and
1486 Ago2 complex was pulled down using anti-Ago2 antibody for spinal tissues 3 days
1487 after CFA injection. $n = 4$ per group; $*p < 0.05$ versus the corresponding Sal groups
1488 by two-tailed paired Student's t test. **C**, **D**, The expression change of Ago2 protein
1489 after intrathecal injection of Lenti-Ago2 in naïve mice or CFA-induced pain mice
1490 (**C**), and knockdown of Ago2 with Ago2-siRNA and PLV-Ago2 in naïve mice (**D**). n

1491 = 4 per group; * $p < 0.05$; one-way ANOVA (expression vs. the treated groups)
1492 followed by post hoc Tukey test. **E, F**, Overexpression of Ago2 decreased the
1493 spinal circRNA-Filip1l content (**E**), but not pre-circRNA-Filip1l content (**F**) in CFA
1494 mice. Spinal cord was collected, respectively hour 3 after intrathecal injection of
1495 Ago2 protein, and day 2 after Lenti-Ago2 intrathecal injection. $n = 5$ per group;
1496 * $p < 0.05$, ** $p < 0.01$; one-way ANOVA (expression vs. the treated groups) followed
1497 by post hoc Tukey test. **G, H**, Knockdown of Ago2 increased the spinal
1498 circRNA-Filip1l expression (**G**), not changed pre-circRNA-Filip1l level (**H**) day 2
1499 after 2 consecutive day's Ago2-siRNA or PLV-Ago2 injections in naïve mice. $n = 5$
1500 per group; * $p < 0.05$, versus the corresponding control groups by two-tailed paired
1501 Student's t test. **I, J**, Overexpression of Ago2 alleviated the thermal hyperalgesia
1502 and mechanical allodynia induced by intrathecal injection of Ago2 (**I**) or
1503 Lenti-Ago2 for 2 consecutive days (**J**) in CFA mice. $n = 6$ per group; * $p < 0.05$,
1504 ** $p < 0.01$; two-way ANOVA (effect vs. group \times time interaction) followed by post
1505 hoc Tukey test. Red arrow, CFA injection; blue arrows, Ago2 or PBS (left) and
1506 Lenti-Ago2 or Lenti-vector (right) injections. **K, L**, Knockdown of Ago2 induced the
1507 thermal and mechanical hypersensitivity after 2 consecutive days' intrathecal
1508 injections of Ago2-siRNA (**K**) or PLV-Ago2 (**L**) in naïve mice. $n = 6$ per group;
1509 * $p < 0.05$, ** $p < 0.01$; two-way ANOVA (effect vs. group \times time interaction) followed
1510 by post hoc Tukey test. Black arrow, Ago2-siRNA or Scr and PLV-Ago2 or Vector
1511 injections. **M**, Inhibiting circRNA-Filip1l with anti-Filip1l prevented the thermal and

1512 mechanical hypersensitivity induced by knockdown of Ago2 after 2 consecutive
1513 day's intrathecal injection of PLV-Ago2 in naïve mice. $n = 6$ per group; $**p < 0.01$;
1514 two-way ANOVA (effect vs. group \times time interaction) followed by post hoc Tukey
1515 test. **N**, Overexpression of miRNA-1224 did not change the pain hypersensitivity
1516 induced by knockdown of Ago2 with Ago2-siRNA for 2 consecutive days
1517 intrathecal injection in CFA mice. $n = 6$ per group; $**p < 0.01$; two-way ANOVA
1518 (effect vs. group \times time interaction) followed by post hoc Tukey test.

1519

1520 **Figure 7.** CircRNA-Filip1l regulates nociceptive response via positively targeting
1521 Ubr5. **A**, Schematic presentation of circRNA-Filip1l binding to near region of Ubr5
1522 TSS. **B**, Validation of circRNA-Filip1l targeting Ubr5 by the use of luciferase
1523 reporter. The activities of the pGL6-Ubr5 encompassing TSS of Ubr5 region
1524 bound by circRNA-Filip1l were detected hour 24 after co-transfection of pGL5 or
1525 pGL6-Ubr5 with DNA3.1-Filip1l by firefly luciferase reporter assays in HEK293T
1526 cells. The pGL6 plasmid (empty vector) was used as the negative control;
1527 pGL6-Ubr5, plasmid with Ubr5 region bound by circRNA-Filip1l. DNA3.1-Filip1l,
1528 plasmid of circRNA-Filip1l overexpression. Values of luciferase activities for each
1529 plasmid were normalized for transfection efficiency by co-transfection with
1530 pRL-TK plasmid. $n = 4$ per group; $**p < 0.01$, $***p < 0.001$; two-way ANOVA (effect
1531 vs. plasmid \times treated interaction) followed by post hoc Tukey test. **C**, Single cell
1532 RT-PCR shows the co-expression of circRNA-Filip1l with miRNA-1224, Ago2, and

1533 Ubr5 in the spinal neurons of mice. No. 7 is a negative control. **D, E**, Knockdown
1534 of Ubr5 reversed the increase of spinal Ubr5 protein 24h after intrathecal injection
1535 of Ubr5-siRNA (**D**) or day 2 after 2 consecutive day's intrathecal injection of
1536 PLV-Ubr5 (**E**) in CFA mice. $n = 5$ per group; $*p < 0.05$, $**p < 0.01$; one-way ANOVA
1537 (expression vs. the treated groups) followed by post hoc Tukey test. **F**, Intrathecal
1538 injection of Ubr5-siRNA for 2 consecutive days alleviated the hypersensitivity to
1539 thermal or mechanical stimulus in CFA mice. Red arrow, CFA or Sal injections;
1540 Blue arrows, Ubr5-siRNA or Scr injections. $n = 6$ per group; $*p < 0.05$, $**p < 0.01$;
1541 two-way ANOVA (effect vs. group \times time interaction) followed by post hoc Tukey
1542 test. **G**, Intrathecal injection of PLV-Ubr5 for 2 consecutive days inhibited the pain
1543 sensitivity in CFA mice. Red arrow, CFA or Sal injections; Blue arrows, PLV-Ubr5
1544 or Vector injections. $n = 6$ per group; $*p < 0.05$, $**p < 0.01$; two-way ANOVA (effect
1545 vs. group \times time interaction) followed by post hoc Tukey test. **H**, Inhibiting
1546 circRNA-Filip1l via intrathecal injection of anti-Filip1l for 2 consecutive days
1547 reversed the increase of Ubr5 protein in CFA mice. $n = 5$ per group; $*p < 0.05$;
1548 one-way ANOVA (expression vs. the treated groups) followed by post hoc Tukey
1549 test. **I, J**, Up-regulating circRNA-Filip1l via intrathecal injections of circRNA-Filip1l
1550 mimics (**I**) or Lenti-Filip1l (**J**) for 2 consecutive days increased the expression of
1551 Ubr5 protein in naïve mice. $n = 5$ per group; $*p < 0.05$, $**p < 0.01$; one-way ANOVA
1552 (expression vs. the treated groups) followed by post hoc Tukey test. **K**, Intrathecal
1553 pre-injection of PLV-Ubr5 for 2 consecutive days prevented the thermal

1554 hyperalgesia and mechanical allodynia induced by circRNA-Filip1I during the
1555 development period. $n = 6$ per group; $*p < 0.05$, $**p < 0.01$; two-way ANOVA (effect
1556 vs. group \times time interaction) followed by post hoc Tukey test. Blue arrow,
1557 PLV-Ubr5 or Vector injections; Red arrow, circRNA-Filip1I mimics or Scr injections.
1558 **L**, Intrathecal post-injection of Ubr5- siRNA for 2 consecutive days inhibited the
1559 pain hypersensitivity induced by Lenti-Filip1I during the development period. $n = 6$
1560 per group; $*p < 0.05$, $**p < 0.01$; two-way ANOVA (effect vs. group \times time interaction)
1561 followed by post hoc Tukey test. Red arrow, Lenti-Filip1I or Lenti-vector injections.
1562 Blue arrow, Ubr5-siRNA or Scr injections.

1563

1564 **Figure 8.** The schematic of miRNA-1224 splicing circRNA-Filip1I in an
1565 Ago2-dependent manner regulates chronic inflammatory pain via targeting Ubr5.

1566

1567

1568

1569

1570

1571

1572

1573

1574

1575 **Table 1.**


1576 Test was performed 48 h after intrathecally injection of mimics, anti-RNA and Scr
1577 or 72 h after intrathecal injection of Lentivirus for 2 consecutive days in mice. No
1578 significance; one-way ANOVA (response time vs. the treated groups) followed by
1579 post hoc Tukey test. SEM given in parentheses. $n = 5$ mice per group; five trials.









1580


1581


1582


1583

















Table 1. Mean changes in locomotor function.

Treatment groups	Locomotor function test		
	Placing	Grasping	Righting
Saline (5 μ l)	5(0)	5(0)	5(0)
Negative control siRNA (Scr)	5(0)	5(0)	5(0)
PLVTHM empty vector (Vector)	5(0)	5(0)	5(0)
Pwpxl empty vector (Lenti-vector)	5(0)	5(0)	5(0)
Sal + Scr	5(0)	5(0)	5(0)
Sal + anti-Filip11	5(0)	5(0)	5(0)
CFA + Scr	5(0)	5(0)	5(0)
CFA + anti-Filip11	5(0)	5(0)	5(0)
Sal + Vector	5(0)	5(0)	5(0)
Sal + PLV-anti-Filip11	5(0)	5(0)	5(0)
CFA + Vector	5(0)	5(0)	5(0)
CFA + PLV-anti-Filip11	5(0)	5(0)	5(0)
circRNA-Filip11 mimics	5(0)	5(0)	5(0)
Lenti-circRNA-Filip11	5(0)	5(0)	5(0)
Sal + miRNA-1224 mimics	5(0)	5(0)	5(0)
CFA + miRNA-1224 mimics	5(0)	5(0)	5(0)
Sal + Lenti-miRNA-1224	5(0)	5(0)	5(0)
CFA + Lenti-miRNA-1224	5(0)	5(0)	5(0)
miRNA-1224 inhibitor	5(0)	5(0)	5(0)
PLV-miRNA-1224	5(0)	5(0)	5(0)